FAMILY CANCER HISTORY AND PEDIGREES AS A PUBLIC HEALTH INTERVENTION FOR PROMOTING HEALTH AND PREVENTING PROSTATE CANCER IN AFRICAN AMERICAN MEN by Wharton, Holisa
Clemson University
TigerPrints
All Dissertations Dissertations
12-2012
FAMILY CANCER HISTORY AND
PEDIGREES AS A PUBLIC HEALTH
INTERVENTION FOR PROMOTING
HEALTH AND PREVENTING PROSTATE
CANCER IN AFRICAN AMERICAN MEN
Holisa Wharton
Clemson University, hwharton@lander.edu
Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Part of the Genetics and Genomics Commons
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Wharton, Holisa, "FAMILY CANCER HISTORY AND PEDIGREES AS A PUBLIC HEALTH INTERVENTION FOR
PROMOTING HEALTH AND PREVENTING PROSTATE CANCER IN AFRICAN AMERICAN MEN" (2012). All
Dissertations. 1014.
https://tigerprints.clemson.edu/all_dissertations/1014
  
 
 
 
 
 
 
 
FAMILY CANCER HISTORY AND PEDIGREES AS A 
PUBLIC HEALTH INTERVENTION FOR PROMOTING 
HEALTH AND PREVENTING PROSTATE CANCER 
IN AFRICAN-AMERICANS 
____________________________________________________ 
 
A Dissertation 
Presented to  
the Graduate School of  
Clemson University  
____________________________________________________ 
 
In Partial Fulfillment  
of the Requirements for the Degree  
Doctor of Philosophy 
Nursing 
____________________________________________________ 
 
by  
Holisa Coleman Wharton 
December 2012 
____________________________________________________ 
 
Accepted by: 
Dr. Julia Eggert, Dissertation Chair 
Dr. Elisabeth Chismak 
Dr. Chin Fu Chen 
Dr. Dewayne Moore 
 
 
 
 ii 
ABSTRACT 
 
 
Prostate cancer is the most common cancer diagnosed in men and the second 
leading cause of cancer death among men in the United States.  African-American men 
have substantially higher prostate cancer incidence and mortality than European-
American men.  It is unclear whether this incidence is due to acquired DNA changes 
(sporadic cancer) or if germline Mendelian genetics/genomics (inherited cancer) is the 
source of this health disparity.  To explore this cause, the focus of this dissertation paper 
is family health history and hereditary prostate cancer.  A family history tool is the most 
commonly used predictive instrument for hereditary prostate cancer.  The identification 
of men with hereditary prostate cancer allows healthcare providers to identify high-risk 
relatives who are more likely to benefit from targeted health promotion and cancer 
prevention programs.  Use of non-validated family history tools may prevent healthcare 
providers from collecting information needed to identify hereditary prostate cancer and 
ascertaining accurate risk assessment in unaffected African-American men.  This pilot 
study was conducted to validate the effectiveness of a family cancer history tool and 
pedigree analysis in the identification of hereditary prostate cancer in a community based 
sample of African-American men.  While small sample size limited the power of the 
analysis, the family history tool and pedigree analysis appears to have analytical validity 
as a public health instrument for identifying hereditary prostate cancer.  Twenty-two 
percent (11 of 49) of consultands reported a personal history of prostate cancer with one 
hereditary prostate cancer family observed.  Age was significantly related to a personal 
history of prostate cancer (p= 0.05) but other known predictors of prostate cancer were 
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statistically undetectable.  The pilot study demonstrated that though the family cancer 
history tool appears to have clinical validity a larger sample is needed to prove clinical 
validity.  Additional research is needed to examine analytical validity, clinical utility and 
ethical, legal and social issues surrounding the use of family cancer history and pedigree 
analysis as a public health intervention for addressing the health disparity of prostate 
cancer in African-American men 
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CHAPTER I 
 
INTRODUCTION 
 
 
In the United States (US), the incidence rate of prostate cancer (PrCa) in African-
American (AfAm) males is nearly double that of European-American (EuAm) males.  
More significant, is the more than double mortality rate due to PrCa between AfAms and 
EuAms.  According to Surveillance Epidemiology and End Results Statistical (SEER) 
Facts Sheets, the mortality rate for AfAm is 53.1 per 100,000 men compared to EuAm at 
21.7 per 100,000 men (Howlander et al., 2012).  Higher incidences of PrCa, the migration 
of initial diagnosis at younger ages, and more aggressive disease at earlier ages in AfAm 
men, imply a genetic predisposition to the malignancy (Mastalski, Coups, Ruth, Raysor, 
& Giri, 2008; Nieder, Taneja, Zeegers, & Ostrer, 2003).  
PrCa is a malignancy with a multifactorial and polygenic etiology (Witte, 2009).  
Seventy-five percent of the total PrCa cases are due to sporadic, or somatic mutations, 
15-20% are due to a combination of environment and inherited genetic susceptibility and 
5-10% are due to highly penetrant, germ-line mutations (National Cancer Institute (NCI), 
2012).  While genetic scientists continue to search for the specific genotypes, family 
history and pedigree analysis are being used by researchers to identify families with the 
phenotype labeled as hereditary PrCa (Bratt, 2002).  Hereditary PrCa is the focus of this 
research; specifically the translatability of comprehensive family history and pedigree 
analysis to first identify and eventually assess the presence of this risk in the AfAm male 
population. 
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The objective for this dissertation research is to examine the feasibility for use of 
comprehensive family history and pedigree analysis, in the public health setting, to 
facilitate identification of AfAm men with hereditary prostate cancer.  The specific aims 
used to meet this objective are the following:  
 
1. Identify families with hereditary PrCa and confirm personal history of PrCa. 
 
a. Use the Hopkins Criteria of hereditary PrCa as defined by Carter et al. 
(1992) and as utilized in genetic research of PrCa to identify pedigrees 
with obvious Mendelian patterns of transmission of PrCa. 
 
b. Determine the proportion of self-reported personal PrCa history that can 
be confirmed through the South Carolina Central Cancer Registry 
(SCCCR) that will serve as a method of identifying PrCa cases. 
 
c. Identify the proportion of at risk individuals in each hereditary PrCa 
family as these individuals are the target of public health educational 
programs. 
 
2. Identify variables in the piloted family cancer history tool that best predict 
hereditary PrCa.  
 
a. H0—There is no relationship between age and personal history of PrCa. 
 
b. H0—There is no relationship between having a father with PrCa and a 
personal history of PrCa 
 
c. H0—There is no relationship between having a father with any cancer and 
a personal history of PrCa. 
 
d. H0—There is no relationship between having a brother with PrCa and a 
personal history of PrCa. 
 
e. H0—There is no relationship between having a brother with any cancer 
and a personal history of PrCa. 
 
f. H0—There is no relationship between having a sister with breast cancer 
and a personal history of PrCa. 
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g. H0—There is no relationship between having a mother with any cancer is 
and a personal history of PrCa. 
 
h. H0—There is no relationship between having multiple brothers with 
cancer and a personal history of PrCa. 
 
3. Evaluate the validity and utility of the piloted family cancer history tool and 
pedigree analysis of hereditary PrCa as used in a pilot sample of southeastern 
AfAm men.  The assumption of this specific aim is that the family cancer risk 
assessment model as evaluated using statistical analysis of family cancer 
history data and pedigree analysis will find significant correlation between 
known family history variables (age, brother with cancer, father with cancer, 
multiple affected first degree relatives.)  
 
a. H0—There is no relationship between known predictor variables of 
hereditary PrCa and personal history of PrCa. 
 
b. H0—There is no relationship between confounding variables (education, 
health insurance, time spent outside during daytime hours) and a personal 
history of PrCa.  
 
The model, which refers to the four domains of the evaluation process; analytic 
validity, clinical validity, clinical utility and associated ethical, legal, and social 
implications, (ACCE) is used as the framework for review of the literature, study design, 
and translation into clinical practice (Yoon, Scheuner, and Khoury, 2003).  See Figure 
1.1. 
 
ACCE Model 
 
Yoon et al. (2003) suggested the ACCE model to evaluate the validity and utility 
of using family history as a tool for predicting risk of genetic disease.  The ACCE model 
was developed by the Centers for Disease Control and Prevention’s Office of Public 
Health Genomics (OPHG) (Centers for Disease Control and Prevention, 2010).  It was 
the first publicly available analytical process for evaluating scientific data on emerging  
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The domains of the ACCE Model and the respective subdomains are used to evaluate genetic 
testing for use in public health practice.  Image from: http//www.cdc.gov/genomic. 
 
Figure 1.1.  ACCE Model. 
 
 
genetic tests.  According to Yoon, et al. (2003) family history can be used as a tool to 
ascertain risk for common, heritable, chronic diseases and thereby identify individuals 
with increased risk of disease susceptibility.  In an earlier article, Yoon, Scheuner, 
Peterson-oehlke, Gwinn, Faucett, & Khoury (2002) state that:  
 
Collection and interpretation of family history has rarely been applied to 
the practice of preventive medicine to assess disease risk and influence 
early detection and prevention strategies.  In this setting, pedigree analysis 
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has primarily been limited to rate cases of cancer or cardiovascular disease 
where a strong genetic component is obvious.  Even when there is a strong 
family history, many of these high-risk people who could benefit from a 
genetic evaluation are missed by their primary care physicians. (pp.305)  
 
In order for a disease to be appropriate for a family history tool to be adapted in 
public health settings, Yoon et al. (2003) noted the disease must be associated with a 
substantial public health burden as assessed in terms of prevalence, morbidity and 
mortality.  As seen in Table 1.1 and Figure 1.2, AfAms are disproportionately affected 
with PrCa.  Additional criteria examined as part of the literature review include the 
following:  well-defined case definition, awareness of disease among relatives, accurate 
reports by family members, and family history as an established risk factor.  Criteria not 
examined in the review but still significant are associated disabilities, healthcare costs, 
and effective interventions for primary and secondary prevention. 
 
Concepts and Assumptions 
 
 This section defines reoccurring terms and concepts for this research effort.  The 
first term is African-American.  
 
African-American (AfAm) 
 
For the purpose of this manuscript, the definition of AfAm will incorporate the 
description published by Agyemang, Bhopal, and Bruijnzeels (2005).  These authors 
note:  
The term AfAm refers to a person of African ancestral origins who self 
identifies or is identified by others as AfAm.  While the term AfAm has 
been used at least since the 1920s, it has been the preferred term in the 
USA since the 1970s.  As most AfAms in the USA originated from sub- 
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Table 1.1.  Prevalence, Morbidity, Incidence, Mortality. 
 
Criteria Statistics 
Prevalence Complete Prevalence  
White—1,984,603 
Black—284,208 
  
Morbidity 5 Year Survival Rate For Men diagnosed in 2003 
White—99.9 
Black—97.5 
  
Incidence Age-Adjusted U. S. Incidence Rates 2004-2008 per 100,000 
White—149.5 
Black—233.8 
  
Mortality Age-Adjusted U. S. Mortality Rates 2008 per 100,000 
White—22.4 
Black—54.9 
 
Table based on SEER incidence and NCHS mortality statistics.  Most can be found 
within:  Howlander, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Waldron, 
W., Alterkruse, S. F., Kosary, C. L., Ruhl, J. Tatalovich, Z., Cho, H., Mariotto, A., 
Eisner, M. P. Lewis, D. R. Chen, H. S., Feur, E. J., Cronin, K. A., Edwards, B. K (eds). 
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gove/csr/1975_2008/, based on November 2010 SEER data submission, 
posted to the SEER web sit, 2011. 
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Table from Cancer Statistics:  Fast Stats http://seer.cancer.gov/faststats/selections.php 
 
Figure 1.2.  SEER data of Age-Specific Incidence Rates by Race/Ethnicity. 
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Saharan Africa, the term is not applied to Africans from northern African-
countries such as Morocco.  Most AfAms are descendants of persons 
brought to the Americas as slaves between the 17
th
 and 19th century 
(distant ancestry).  Such people differ from others who came from Africa 
or the Caribbean in the 20
th
 and 21st centuries (recent ancestry), in terms 
of culture, language, migration history, and health (Agyemang et al., 2005, 
pp. 1016). 
 
 
Family and Family Health History 
 
 From the paradigm of healthcare genetics, family is defined as biologically related 
individuals sharing common genetic information, such as genes, allelic variants and 
frequencies due to a common ancestor.  Family can be further characterized by parental 
lineage (maternal or paternal side of the family) and degree of relatedness (first- degree- 
parent, siblings, children; second degree- aunts, uncles, grandparents, nieces, and 
nephews).  The family structure is dynamic in that it continually changes due to marriage, 
divorce, adoption, birth and death.  The concept of family is also complex as it is 
influenced by beliefs about inheritance, cultural practices, political and socioeconomic 
factors, i.e., half-siblings, stepparents, same sex marriage, consanguinity, co-habitation, 
and polygamy (McBrath and Edwards, 2009).   
The family health history describes the disease history of relatives and identifies 
potential genetic relationships.  In order to estimate an individual’s hereditary cancer risk, 
it is essential to summarize family cancer history information in the form of a pedigree 
(National Cancer Institute, 2012).   
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Pedigree 
 
A medical pedigree is a standardized diagrammatic presentation of family 
relationships in which patterns of disease transmission are tracked.  The diagrammatic 
illustration facilitates the depiction of a family’s health history and genetic relationships 
(Bennett, French, Resta, & Doyle, 2008).  
Pedigrees used specifically for risk assessment should include a minimum of 3 
complete generations (Murff, Spigel, & Syngal, 2004).  The pedigree should contain 
information such as age or year of birth, age and cause of death, ethnic background of 
each grandparent, the status of each relative as affected or unaffected, age at disease 
onset, and other pertinent healthcare information (Bennett et al, 2008).  Hereditary PrCa 
is indicated if the pedigree reveals:  multiple PrCa in close relatives, early age of onset (< 
55 years), and recognizable Mendelian inheritance pattern (Carter, Beaty, Steinberg, 
Childs, & Walsh, 1992.)  
 
Hereditary PrCa 
 
In 1992, Carter used family history to define hereditary PrCa.  An individual was 
considered as being at risk for hereditary PrCa if his family history revealed PrCa in the 
following areas: 
 
 Three or more first-degree relatives (father, brother, son). 
 
 Three successive generations of either the maternal or paternal lineages 
(Mendelian pattern of inheritance). 
 
 At least two relatives affected at or before the age of 55 years. 
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Whereas men with familial PrCa also had a positive family history, it was weakly 
positive and insufficient to satisfy the hereditary PrCa criteria.  Patients with no known 
family history were considered to have acquired or sporadically induced PrCa (Carter et 
al., 1992).  In a study of the clinical impact of different definitions of hereditary PrCa, 
Sacco, et al., (2005) simplified the definitions as:  “Sporadic PrCa is cancer occurring 
randomly in the population; familial PrCa is unpredictable clustering of PrCa in families; 
and, hereditary PrCa is a strong clustering and early onset of PrCa.” pp. 762. 
Carter et al. (1992) concluded that 43% of early age onset PrCa (disease onset 
<55 years of age) was due to autosomal dominant inheritance of a rare allele.  More 
importantly, it was noted that early age onset hereditary PrCa constituted only a small 
proportion (9% by age 85) of all PrCa occurrence.  The results of this study found that 
only 2% of PrCa in US Caucasian men occurs in those aged less than 55.  Finally, Carter, 
et al. (1993) concluded that the impact of hereditary PrCa in the population is the greatest 
at younger ages.   
 
Conclusions 
 
PrCa is a public health problem and a source of health disparity in AfAm 
populations.  Health disparities adversely affect groups of people who have 
systematically experienced greater obstacles to health based on but not limited to their 
racial or ethnic groups, socioeconomic status, gender; age, cognitive ability, physical 
ability, geographic location or other characteristics historically linked to discrimination or 
exclusion (US Department of Health and Human Services, 2010). 
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The first step to resolving any problem no matter the source of the problem is 
awareness and acknowledgment of a problem.  In the US, discussion of ethnicity/race 
differences can make for a very sensitive and emotionally charged debate.  In healthcare 
genetics, ethnicity/race is a phenotype that must be considered when assessing risk of 
malignancy and given just as much, if not more weight when assessing, considering 
prognosis, and reoccurrence of malignancy.  Though no sharp genetic boundaries can be 
drawn between ethnically/racially diverse groups, there are variations in frequency of 
certain polymorphisms and haplotypes within and among populations (Bonham, 
Warshauer-Baker, & Collins, 2005).  The discovery of such variations helps researchers 
and clinicians to understand why AfAm men are disproportionately burdened with PrCa.  
According to a recent Cancer Disparity Factsheet published by the National Cancer 
Institute of the National Institute of Health (NIH), nearly all of the genetic variants 
associated with an increased risk of developing PrCa were most often found in AfAm 
men.  Certain combinations of these polymorphisms are associated with a five-fold 
increased risk of PrCa in AfAm men (National Cancer Institute, 2012).   
The remainder of this document is comprised of three manuscripts.  The first 
manuscript is a systematic literature review, utilizing the ACCE model to examine the 
literature to document the validity and utility of family history survey as a predictive test 
for hereditary PrCa.  The second manuscript details a feasibility study to evaluate the 
clinical validity of a specific family history survey and pedigree analysis in a community-
based, sample of AfAm men in South Carolina, non-selected for family history status or 
disease status.  The third manuscript presents a case report illustrating the clinical utility 
12 
 
of the piloted family history tool and pedigree analysis to identify and assess risk of 
hereditary PrCa in a family with multiple cases of PrCa.  Together these three 
manuscripts help to further define the phenotype of hereditary prostate cancer, present the 
body of evidence related to family history and pedigree analysis as it relates to hereditary 
PrCa.  Finally, a case report will illustrate how the researcher envisions translation of 
comprehensive family history and pedigree analysis of hereditary PrCa into public 
healthcare.   
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CHAPTER II 
 
MANUSCRIPT I:  THE ACCURACY AND RELIABILITY OF A FAMILY CANCER 
HISTORY ASSESSMENT IN PEDIGREE RESEARCH OF HEREDITARY PRCA IN AFAMS 
 
 
Abstract 
 
Background 
 
Family history survey is the most commonly used predictive instrument for 
hereditary cancers, including PrCa.  Early identification of African-American men with 
hereditary PrCa is critical in order to promote health in men of high-risk families.  This 
manuscript presents a systematic review of 12 studies, which delineate the relationship 
between family history and risk of hereditary prostate cancer. 
 
Method 
 
The domains of the ACCE model served as the framework for reviewing the 
literature related to the utilization of family history as a public health nursing intervention 
in African-American communities.  The analytical and clinical validity of family history 
relative to prostate cancer is strong but the evidence of the clinical utility is lacking.  
 
Results 
 
Eighteen articles were found that address one or more of the four domains of the 
ACCE model.  Of the eighteen articles, seven reported on cohort studies and 2 reported 
on case control studies.  Five articles addressed analytical validity of family history in 
predicting prostate cancer.  Two articles addressed clinical validity of family history and 
prostate cancer.  Five articles addressed the clinical utility of family history in improving 
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healthcare outcomes related to prostate cancer.  Eight articles addressed the ethical, legal 
and social implications of family history and hereditary disorders, but not specific to 
prostate cancer. 
 
Conclusion 
 
The analytical validity of family history of hereditary prostate cancer is relatively 
strong when compared to other common hereditary cancers, such as breast and colon.  
Most of the subjects in the selected studies recalled and document their family history of 
prostate cancer with high levels of accuracy.  The clinical validity of family history as an 
instrument to stratify risk and predict future disease in an individual is not as well 
supported.  Likewise, the evidence supporting the clinical utility of family history in 
improving health outcomes for men with prostate cancer is weak.  There were no ethical, 
legal, or social issues specific to family history and prostate cancer.  But the ethical, 
legal, and social issues are related to the potential for breach of privacy and 
discrimination inherent to the nature of family health history and genetic information.  
Additional quantitative and qualitative research is needed to evaluate the benefit and risk 
of family history as a public health intervention method for addressing the health 
disparity of prostate cancer in African-Americans.  
 
Key Words 
 
Family history, prostate cancer, African-American, hereditary, ACCE model, 
analytical validity, clinical validity, and clinical utility. 
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Introduction 
 
 Prostate cancer (PrCa) is the second most common cause of cancer death in men 
(Center et al., 2012).  The greatest risk for PrCa is found in older men, African-American 
(AfAm) men, and men with a family history of PrCa.  It is not clear why AfAm are at an 
increased risk of developing and dying from PrCa.  It is suspected that part of this 
disparity is due to delayed diagnosis and limits in access to healthcare.  Some studies 
have suggested a genetic predisposition contributes to the increased prevalence and 
mortality of PrCa in AfAm (Center et al., 2012).  
 The risk of PrCa increases dramatically in AfAms with a family history of PrCa.  
AfAm men with a father or brother with PrCa have a one in three chance of developing 
the malignancy.  The risk increases to 83% with two affected first-degree relatives and 
increases to 97% if they have three first-degree relatives with PrCa.  It is not clear what 
role hereditary PrCa plays in the increased incidence and mortality among AfAms 
(Center, et al., 2012).  
 This systematic review of published literature used the ACCE model as 
recommended by Yoon, Scheuner, & Khoury (2003) to improve understanding related to 
factors that contribute to validity and utility of family cancer history data for hereditary 
PrCa.  The overall aim of this search strategy was to facilitate the examination of all 
relevant published studies to identify family cancer assessment methods used in 
American populations.  Knowledge from such studies will be used to provide evidence 
for the development of a valid family cancer history assessment tool and pedigree 
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analysis protocol for use in public health and preventive medicine to identify AfAm men 
with hereditary PrCa.  
 
Model 
 
According to Yoon, Scheuner, & Khoury (2003), family history can be used as a 
tool to stratify risk for common chronic diseases and thereby identify individuals with 
increased risk of disease susceptibility.  Yoon recommends a model developed by the 
Center for Disease Control and Prevention’s Office of Public Health Genomics (OPHG) 
(Centers for Disease Control and Prevention, 2010).  The model refers to the four 
domains of the evaluation process:  analytic validity, clinical validity, clinical utility and 
associated ethical, legal, and social issues that influence both validity and utility (ACCE).  
Initially the model was used to evaluate the validity and reliability of genetic tests.  Yoon 
suggest it is also may be used to evaluate the validity and utility of using family history 
as a tool for predicting risk of hereditary disease.  There are no existing studies that use 
the ACCE model to examine the effectiveness of family history and disease. 
The ACCE model is composed of a standard set of 44 questions and builds on 
previously published methodologies and terminology introduced by the Secretary’s 
Advisory Committee on Genetic Testing (Gudgeon, McClain, Palomaki & Williams, 
2007).  When implemented in its entirety, the ACCE model can require a year or more to 
complete.  Yoon et al. (2003) proposed a specific set of questions adapted from the 
original 44 questions for the assessment of the validity and utility of family history 
information for disease prevention.  See Table 2.1 for the list of questions used to assess  
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Table 2.1.  Questions for Assessing Literature using ACCE Domains. 
 
 
Analytic Validity Questions 
1. What is the sensitivity and specificity for reporting each disease included in the tool? 
2. How does the sensitivity and specificity vary by: 
 a. Type of relative 
 b. Proband characteristics 
 c. Disease Characteristics 
 d. Disease terminology 
 e. Phrasing of the question 
3. How accurate is age of onset information? 
4. What settings yield more valid information? 
5. What formats yield more valid information? 
6. What gold standards exist to validate the reported data? 
 
Clinical Validity Questions 
7. What is the natural history of the disease (may determine when family history should 
be ascertained)? 
8. Are there effective interventions for primary and/or secondary prevention? 
9. Is there general access to the interventions? 
10. What strategies could be adopted to improve compliance with recommended 
interventions? 
11. Are educational materials available to explain familial risk and the recommended 
interventions?  
12. What is the short-term and long-term impact of positive or negative family history or 
screening and disease prevention? 
13. Are there any health risks associated with the family history assessment and 
subsequent interventions? 
14. What are the financial costs associated with the family history assessment? 
15. What are the economic benefits associated with interventions resulting from the 
assessment? 
16. What methods exist for evaluating and monitoring the family history assessment 
process and its benefits and risks? 
 
Clinical Utility Questions 
17. What is the natural history of the disease (may determine when family history should 
be ascertained)? 
18. Are there effective interventions for primary and/or secondary prevention? 
19. Is there general access to the interventions? 
20. What strategies could be adopted to improve compliance with recommended 
interventions? 
21. Are educational materials available to explain familial risk and the recommended 
interventions? 
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Table 2.1.  Questions for Assessing Literature using ACCE Domains. (continued) 
 
 
22. What is the short-term and long-term impact of positive or negative family history or 
screening and disease prevention? 
23. Are there any health risks associated with the family history assessment and 
subsequent interventions? 
24. What are the financial costs associated with the family history assessment? 
25. What are the economic benefits associated with interventions resulting from the 
assessment? 
26. What methods exist for evaluating and monitoring the family history assessment 
process and its benefits and risks? 
 
ELSI Questions 
27. Are there legal issues regarding informed consent, ownership of the data, obligation 
to disclose, or reporting requirements? 
28. What is known about stigmatization, discrimination, privacy/confidentiality, and 
personal/family and social issues associated with family history assessment and risk 
labeling? 
29. What safeguards have been described to protect privacy and are these safeguard in 
place and effective? 
 
Table adapted from Yoon, P. W., Scheuner, M. T., Peterson-Oehlke, K. L., Gwinn, M., 
Faucett, A., Khoury, M. J. (2002).  Can family history be used as a tool for public health 
and preventive medicine?  Genetics in Medicine, 4, 304-310. 
 
 
the literature in this review process.  This literature review uses these 29 questions to 
examine the literature related to family history and PrCa. 
 
Disorder, Setting and Test 
 
The presence of hereditary PrCa was first identified using diagrammatic family 
history.  This enabled the development of a description of a variant of PrCa distinguished 
by early onset and autosomal dominant inheritance (Carter, Beaty, Steinberg, Childs, & 
Walsh, 1992).  Nearly two decades later, researchers still only identify hereditary PrCa 
cases using family cancer history.  Though there are several PrCa susceptibility gene 
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variants, there is no clinically useful genetic test for hereditary PrCa.  Hereditary PrCa is 
correlated with a positive family history of PrCa including early age of onset, multiple 
affected relatives, and a pedigree with an obvious Mendelian pattern of inheritance 
(Carter, et al., 1992).  Familial PrCa correlates with a positive family cancer with a 
pedigree of at least two affected relatives but no indication of a Mendelian pattern of 
inheritance (Carter, et al., 1992).  In a sample of 95.5% European American (EuAm) 
men, a group of researchers (Carter, Bova, Beaty, Steinberg, Childs, Isaacs, & Walsh, 
1993) found that hereditary PrCa represented 5-9% of the total PrCa cases.  Familial 
PrCa represented 10-20%, with sporadic PrCa making up the majority at 74% of all PrCa 
cases in the sample.  These percentages are based on a EuAm majority sample, and 
continue to be referenced and published as the prevalence of hereditary PrCa, familial 
PrCa and sporadic PrCa within the US general population.  
The health disparity of PrCa between AfAm and EuAm men is well documented 
(Albain K.S., Unger, J. M., Crowley J. J., Coltman, C. A., & Hershman, D. L. 2009; 
Jemal et al., 2008, Major, Oliver, Doubeni, Taskler, Keating, & Cutler, 2012).  However, 
the impact of hereditary PrCa on the incidence and mortality disparity of PrCa in AfAm 
men is relatively unknown and needs further study.  A recent Cancer Disparity 
Factsheet, published by the National Cancer Institute (NCI) of the National Institute of 
Health (NIH), states that nearly all of the genetic variants associated with an increased 
risk of developing PrCa are found most often in AfAm men.  Certain combinations of 
these polymorphisms are associated with a five-fold increased risk of PrCa in AfAm men 
(National Cancer Institute, 2008).  Given the correlation of hereditary PrCa with higher 
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incidence of PrCa, migration toward younger ages, and more aggressive disease at earlier 
ages this review focuses on evaluating the use of a family history survey as a public 
health intervention to identify hereditary PrCa, assisting in the ultimate goal of 
decreasing mortality in AfAm men.  
Public health nurses monitor health trends and identify health risk factors unique 
to specific communities.  They set local priorities for health-related interventions to 
provide the greatest benefit to the most people.  Public health nurses design and 
implement health education campaigns and disease prevention activities, market locally 
available health care programs and services to improve knowledge about access to care.  
They also educate and provide direct health care services to vulnerable and at-risk 
populations (American Nurses Association, 2007).  
As baccalaureate nurse educators begin to incorporate the Essentials of Genetic 
and Genomic Nursing Competencies, Curricula Guidelines, and Outcome Indicators 
(Consensus Panel on Genetic/Genomic Nursing Competencies, 2009) into their 
respective curricula, new graduates will be better prepared than their predecessors to 
acquire multi-generational family history data and develop pedigrees from the data.  
Advance practice nurses will also be prepared to analyze family history data and 
pedigrees and estimate risks for Mendelian and multifactorial disorders as Essential 
Genetic and Genomic Competencies for Nurses with Graduate Degrees was made 
available to practitioners in 2012 (Greco, Tinely, & Seibert, 2012). 
Without a genetic test for even one highly penetrant gene variant for hereditary 
PrCa, family history remains one of the most commonly used methods for identifying 
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individuals and families with possible causative variants of hereditary PrCa (Colloca & 
Venturino, 2011).  Family history of cancer incidence information is collected in 
genetic/genomic research and is used to infer risk of disease in population-based, case-
control, cohort and family-based studies; yet little information is available on the 
accuracy of reported family cancer history of AfAms.  Most studies that have examined 
the validity of family cancer history have included primarily EuAm samples, therefore 
limiting the generalizability of their findings to AfAm men (Cerhan, et al., 1999; Keetch, 
Humphrey, Smith, Stahl, & Catalona, 1996; Lesko, Rosenberg, & Shapiro, 1996; Spitz, 
Currier, Fueger, Babaian, & Newell, 1991; Steinberg, Carter, Beaty, Childs, & Walsh, 
1990).  
 
Family Health History and Pedigree Analysis in Clinical Practice 
 
Healthcare providers use family health history information to determine if there is 
an increased risk of illness based on incidence in the family history.  Once risk is 
determined, family history information is also considered when making clinical decisions 
about treatment of disease.  Family health history data is typically obtained by response 
to a questionnaire.  The questionnaire can be formulated as an electronic, interactive or a 
written document.  The information from the family health history questionnaire can be 
transcribed into a pedigree for a more rapid and easier interpretation.    
A pedigree is a standardized diagrammatic representation of family relationships 
in which patterns of disease transmission are tracked.  The diagram facilitates 
identification of patterns of inheritance and potentially shared environmental risk factors.  
The pedigree should review at least three generations (Brock, Allen, Kieser, and 
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Langlois, 2010) and contain information for the individual and relatives such as, relevant 
health information, illnesses and age at diagnosis, ethnic background, age at and cause of 
death, information of half siblings and consanguinity (Bennett, et al., 1995 & Brock, et 
al., 2010).  In addition the pedigree should be an evolving part of the medical record, 
updated routinely along with medications, health history, and surgical history (Brock et 
al., 2010).  
 
Family History and Pedigree Analysis in Clinical Research 
 
 Family cancer history data is a critical variable in pedigree research.  The 
pedigree developed from the family cancer history data is used to identify people with 
increased risk for genetic disorders or with susceptibility to disease.  Pedigree research is 
often the precursor to genome-wide association studies and linkage analysis studies used 
to discover genotypes associated with a disease or intermediate phenotype.  Importantly, 
pedigree research relies on accurate ascertainment of family history.  One should suspect 
hereditary cancer if the pedigree reveals multiple first-degree (FDR) and/or second-
degree (SDR) relatives affected with the same cancer, early age of onset, and 
recognizable Mendelian inheritance pattern (Bastacky, Wojno, Walsh, Carmichael, & 
Epstein, 1995; Carter et al., 1992; Carter et al., 1993; Spitz et al., 1991). 
 
Family History and PrCa 
 
There are three different epidemiological forms of PrCa: sporadic, familial, and 
hereditary (Carter et al, 1992).  Studies have concluded that there are no pathological 
differences among these three epidemiological forms of PrCa (Bastacky et al., 1995; 
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Kang, Maygarden, Mohler, & Pruthi, 2004; Keetch, et al., 1996).  Currently there is no 
clinical testing for genes involved in hereditary PrCa.  In the sentinel study described 
below, Carter and colleagues at Johns Hopkins University provided the first definition for 
hereditary prostate cancer, referred to as the Hopkins Criteria, and 20 years later is still 
the only method to identify hereditary PrCa. 
In 1992, Carter used family history to define hereditary PrCa.  An individual was 
considered as having hereditary PrCa, if his family pedigree revealed a history of PrCa in 
the following areas:  
 
1. Three or more first-degree relatives (father, brother, son);  
 
2. Three successive generations of either the maternal or paternal lineages; or 
 
3. At least two relatives affected at or before the age of 55 years. 
 
 
Men with familial PrCa also had a positive family history, but it was weakly positive and 
insufficient to satisfy the hereditary PrCa criteria.  Patients with no known family history 
were considered to have sporadically induced PrCa (Carter et al., 1992).  In a study of the 
clinical impact of different definitions of hereditary PrCa, Sacco et al. (2005) simplified 
the definition by stating “Sporadic PrCa is cancer occurring randomly in the population, 
familial PrCa is unpredictable clustering of PrCa in families and, hereditary PrCa is a 
strong clustering with early onset of PrCa in families” (pp. 762). 
Carter et al. (1992) concluded that 43% of early age onset PrCa (disease onset 
<55 years) was due to autosomal dominant inheritance of a rare allele.  More importantly, 
the group of researchers noted that early age onset hereditary PrCa constituted only a 
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small proportion (9% by age 85) of all PrCa occurrences.  This study results indicated 
that only 2% of PrCa in EuAm men occurs in those aged less than 55.  The same authors 
concluded that the impact of hereditary PrCa in this population is the greatest in the 
younger ages, less than 55 years of age (Carter et al., 1993).   
 
Methods 
 
Identification of Research Literature 
 
Literature searches regarding utilization of family history and pedigree analysis as 
a risk assessment tool for PrCa were conducted using PubMed and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL).  A comprehensive literature search was 
conducted for literature published between 2002 and 2012 using the search term(s) family 
history, AfAm, and hereditary PrCa.  The PubMed, Search Details feature, was reviewed 
for accurate query translation of search terms and identification of Mesh terms.  For a 
summation of numbers of articles identified for review, see Table 2.2.  Additional articles 
(15/18 83%) were ascertained by manually searching through references cited in 
publications.  
 
Selection of Studies 
 
 The following criteria were used to guide selection of articles for review.   
 
Inclusion criteria:   
 
1. Published in the English language.   
 
2. Utilized assessment of family history for PrCa.  
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Table 2.2.  Selection of Studies. 
 
 
Database 
 
Search Terms 
No. of Articles 
Returned 
PubMed 
(1/1/2002-1/1/2012) 
Hereditary Prostate Cancer 55 
Hereditary Prostate Cancer + Family History 31 
Hereditary Prostate Cancer + Family History + 
African-American 
5 
   
CINAHL 
(1/1/2002-1/1/2012) 
Hereditary Prostate Cancer 5 
Hereditary Prostate Cancer + Family History 1 
Hereditary Prostate Cancer + Family History + 
African-American 
1 
 
Literature searches using PubMed and CINAHL was conducted for literature published 
between 2002 and 2012 using the search term(s) family history, AfAm, and hereditary 
PrCa. 
 
 
3. Research originated from an American institution of higher learning or health 
agency.  
 
4. Address one of the four domains of the ACCE model. 
 
Exclusion criteria:  
 
1. Primary focus was linkage or association of specific gene(s) or 
polymorphism(s)  
 
2. Research originated outside of the US.   
 
3. Focused on secondary prevention, such as, family history and reoccurrence 
after radiation therapy. 
 
4. Examined family history of cancer sites other than PrCa. 
 
 
Thirty-three (35%) of the 94 studies found in PubMed originated outside of the 
United States.  Four studies focused on secondary prevention methods and two examined 
family history reports of other cancers in men with PrCa.  The seven studies from the 
CINAHL were also reported in PubMed.  After applying the exclusion criteria 55 articles 
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remained.  The abstracts for these 55 articles were reviewed for relevance to the ACCE 
Model domains.  Eighteen articles addressed at least one of the four ACCE domains.  
Seven (38%) of the eighteen articles reported on cohort studies.  The remaining articles 
consist of two case control studies, one review article, one segregation analysis study, 
three articles discussed ethical, legal or social implications and three articles address 
clinical utility.  See Table 2.3 for a list of the literature by ACCE domain.  
 
Study Quality Assessment 
 
To evaluate the quality of the cohort studies and the case control studies the 
Critical Appraisal Skills Program (CASP) was used because of its specificity for case and 
cohort studies (Public Health Resource Unit, 2006).  The CASP case-control study 
appraisal tool consists of eleven questions designed to assist the reviewer to assess study 
validity, results and relevance systematically (Public Health Resource Unit, 2006).  
Similarly, the CASP cohort study appraisal tool consists of twelve questions designed to 
assist the reviewer to systematically assess study validity, results and relevance (CASP, 
2004).  The CASP tool is designed so that the reviewer can answer yes, can’t tell or no to 
each of the questions.  To facilitate the quantitative evaluation of each study the reviewer 
assigned a score for each response 2 = yes, 1 = can’t tell and 0 = no.  The seven cohort 
studies were given an average score of 20.4.  The two case control studies received scores 
of 18 out of possible 22 points.  Most of the points were lost when asked if the study 
results could be applied to the local population.  Only two of the studies included AfAms 
in the sample. 
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Table 2.3.  Literature Review Articles by ACCE Domain. 
 
ACCE Model Domain Review Articles by Domain 
 
Analytical Validity 
 
Carter et al., 1992 
Kerber & Slattery, 1997 
King et al., 2002 
Ziogas & Anton-Culver, 2003 
Weinrich et al., 2002 
  
Clinical Validity Makinen et al., 2002 
Ziogas & Anton-Culver, 2003 
  
Clinical Utility Cotter et al., 2002 
Carter et al, 1992 
Drake et al., 2008 
Beebe-Dimmer et al., 2006  
Madersbacher et al., 2010 
  
Ethical, Legal, & Social Issues Yoon et al., 2003 
Steck & Eggert, 2011 
Bratt et al., 2006 
Bloom et al., 2008 
Giovannuci et al., 2007 
Spain et al., 2008   
Weinrich et al., 2007   
Bonham et al., 2005 
 
Selected articles for review.  Inclusion criteria include:  (1) English language, (2) use of 
an assessment of family history for PrCa and (3) research originates from an American 
institution of higher learning or health agency. 
 
 
Results 
 
Analytic Validity 
 
In this review, analytic validity refers to how accurately family history tools 
measure for hereditary PrCa among the respondent’s relatives.  Analytic validity can be 
separated into measures of sensitivity and specificity.  Analytic sensitivity is a measure of 
how well the family history tool identifies relatives who have been diagnosed with the 
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disease of interest; in this review, it designates hereditary PrCa (Carter et al., 1992).  
Analytic specificity is a measure of how well the family history tool identifies relatives 
who do not have hereditary PrCa.  Three studies examined the accuracy of a family 
cancer history assessment related to PrCa.  
The earliest of the three studies evaluated the sensitivity of subjects’ self-reported 
family history for seven cancers recorded as a part of the Diet, Activity, and 
Reproduction in Colon Cancer (DARCC) Study in the Utah Population Database (UPDB) 
(Kerber & Slattery, 1997).  Subjects were asked to enumerate their first-degree relatives 
(parents, siblings, and children) by name and to identify the current age of each as well as 
the family members who were dead and their age at death.  Subjects were asked if each 
relative had ever been given a diagnosis of cancer, and if a cancer diagnosis was reported, 
to identify the type of cancer from a list.  The Utah Cancer Registry, a population-based 
cancer registry, was used to determine cancer incidence for the subjects’ relatives.  The 
linked UPDB-Utah Cancer Registry data were not complete and therefore did not serve 
as a perfect “gold standard” to compare the DARCC interview data, but any cancer 
recorded by the Utah Cancer Registry data for a family member identified through the 
UPDB was regarded as confirmed.  The ability to confirm reports allowed for the 
calculation of sensitivity of the subjects’ reports (Kerber & Slattery, 1997).   
Kerber & Slattery (1997) found that sensitivities for breast (83%), colorectal 
(73%), and prostate (70%) were all high and varied little between cases and controls.  
The overall agreement (k; k=1 is total agreement) behaved in similar fashion.  Agreement 
was highest overall for breast cancer (k=0.61) and PrCa (k=0.61), colorectal (k=0.56) 
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cancers were also viewed as being reported accurately.  The DARCC subjects were found 
to report family histories of cancer with 70-90 percent sensitivity and with little 
suggestion of recall bias.  However, there was considerable variability among the 
reported sites of the familial cancer in question.  It was also noted that there was a high 
degree of accuracy for reports of prostate, breast and colorectal cancers (Kerber & 
Slattery, 1997). 
King, Tong, Pack, Spencer, & Amos (2002) evaluated the feasibility of family 
cancer history documentation in a sample of male patients (n=442) with PrCa seen in the 
Prostate Clinic at the University of Texas M. D. Anderson Cancer Center.  
Documentation was defined as “the percentage of records for which credible records 
were obtained” (King et al., 2002 p. 547).  Accuracy was defined as, “the percentage of 
documented cancers that agree with the proband’s report” (King et al. 2002 p. 547).  
Documentation and accuracy rates were provided for eighteen different cancers reported 
by PrCa probands.  Several cancers were reported with 100% accuracy including bladder, 
brain, esophageal, kidney, lymphoma, melanoma, and pancreas.  Breast cancer was 
reported with 95% accuracy and PrCa was reported with 86.2% accuracy (King, et al., 
2002). 
Though the King et al. (2002) study did not report the sensitivity and specificity 
of their family history tool, these measures were calculated based on the data provided in 
the article.  There were a total of 42 cases of PrCa reported.  Of these cases, 25 were 
confirmed.  Thirteen cases of reported PrCa were not confirmed.  By extrapolating the 
missing data the sensitivity was calculated as 96.15% with a specificity of 43.33%.  
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Based on self-reported family cancer history, the researchers were able to document or 
confirm 96.15% of the PrCa cases.  Conversely, the authors were unable to document or 
confirm 57% of the self-reported PrCa cases (King et al, 2002).  
Ziogas & Anton-Culver (2003) systematically evaluated the consistency of 
proband-reported information on cancer in their first-, second-, and third degree relatives.  
The objective of the study was to determine the probability of agreement between the 
proband-reported statuses of cancer in a relative with the reference standard for various 
cancer sites.  This study was conducted at the University of California at Irvine, during 
the creation of the proband family registries for breast, ovarian and colorectal cancers.  
Malignancies reported for the relatives of the proband were verified by obtaining one of 
several types of records—(a) pathology reports, tumor tissue samples, or clinical records; 
(b) “self-reports” from affected and non-affected relatives of probands through structured 
questionnaire and personal interviews; or (c) death certificates on deceased relatives.  
This study found that the probability of agreement (PAC) for PrCa was 79.3 (70.0-88.6) 
and the probability of agreement for no cancer (PANC) 98.8 (98.4-99.5) in first-degree 
relatives.  For second-degree relatives, the PAC for PrCa was 66.7 (55.1-78.2) and the 
PANC was 98.1 (97.2-99). 
Weinrich, Faison-Smith, Hudson-Priest, Royal, & Powell (2002) queried subjects 
of the AfAm Hereditary PrCa Study to examine the stability of self-reported family 
history of PrCa among AfAm men.  Weinrich et al. (2002) reported the reliability of self-
reported family history of PrCa in men asked about family history of PrCa on two 
separate occasions; at the beginning and end of a one-year period.  Their study found that 
33 
 
one year after providing initial responses to family history of PrCa questions, 48% of the 
AfAm men provided different answers (Weinrich et al., 2002).   
The most important implications for research and practice gathered from the 
literature are family history data should be validated using a “gold standard” to ensure 
clinical decision making and research analysis is based on the most accurate data (Kerber 
& Slattery, 1997; King et al., 2002; Weinrich et al., 2002; Ziogas & Anton Culver, 2003).  
These ‘gold standards’ for verification of self-reported family health history can include 
medical records, personal reports, and death certificates.  Family history data researchers 
and clinicians should note that family cancer history of first-degree relatives is 
consistently found to be more accurate than that of second- and third-degree relatives 
(Weinrich et al., 2002; Ziogas & Anton Culver, 2003).  
 
Clinical Validity  
 
Clinical validity (CV) refers to how well family history of disease can be used to 
stratify disease risk and predict future disease in an individual.  Similar to analytical 
validity, CV is measured in terms of sensitivity and specificity.  Clinical sensitivity is 
estimated by the family history of a particular disease among a population based-group of 
people with that disease.  Clinical specificity is estimated by examining family history for 
a particular disease among a population-based group of people without the disease.  
In addition to sensitivity and specificity, the positive and negative predictive 
values are also considered.  In this review, positive predictive value is defined as the 
probability that a person will have hereditary PrCa given their family history meets the 
predetermined criteria.  Likewise, negative predictive value is the probability that a 
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person will not develop hereditary PrCa, if their family history does not meet the 
predetermined criteria.  Two studies reported the clinical validity of family history related 
to PrCa. 
No American studies thoroughly examined clinical validity of family history in 
relation to PrCa.  Therefore, the following Finnish study was included in the review to 
illustrate how clinical validity could be assessed in future American studies.  In the first 
round of the Finnish PrCa screening trial, Makinen et al. (2002) assessed the importance 
of family history at the population level, in terms of program sensitivity and specificity.  
Information on family history was obtained by use of a questionnaire at the time of 
invitation.  If the subject reported one or more first-degree relatives diagnosed with PrCa, 
the family history was regarded as positive.  Of the sample (N=20,311) providing family 
history information through the self-administered questionnaire, 964 (4.7%) reported a 
positive family history (one or more affected first-degree relatives).  In the screened 
population, 502 cancers were detected with only 29 cases reported by men with a positive 
PrCa family history.  The program sensitivity for a positive family history as a 
supplemental screening test was 5.9% (95% CI, 4.0% to 8.4%; 29 of 491).  Importantly, 
restriction of screening to the 29 men with a positive family history would have missed 
94.1% of all PrCas detectable by screening.  However, the specificity for family history 
was 99.6%, limiting screening to men with positive family history would have correctly 
identified 99.6% of men without the cancer.  Inconsistent with other studies, this study 
found that family history was not a good prognostic indicator for early detection of PrCa 
among Finnish men with a family history (Makinen et al., 2002).  Makinen et al. (2002) 
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did address hereditary factors and found that the corresponding population-attributable 
risk was 1.2%.  They went on to conclude that identification of family with strong 
hereditary component demonstrates the existence of genetic factors, but provides little 
information regarding their importance at the population level.   
 Ziogas & Anton-Culver (2002) examined the validity of reporting family history 
of cancer by probands in population-based and clinic-based family registries of breast, 
ovarian, and colorectal cancers.  In addition to calculating the sensitivity and specificity, 
the positive and negative predictive values were calculated on the cancer status of 
relatives by using a reference standard as described under analytic validity.  The positive 
predictive value in first-degree relatives for PrCa was 86.7% range:  74.7-94.5 and the 
negative predictive value was 97.9 range:  96.3-99.7.  The positive predictive value was 
lower for second- and third-degree relatives (Ziogas & Anton-Culver, 2002). 
 
Clinical Utility 
 
 Clinical utility refers to the assessment of the impact and usefulness of the family 
history tool for individuals, families and society.  Clinical utility addresses questions such 
as if the family history information can be used to motivate a behavior change, can 
classification of individuals into risk groups improve the effectiveness of available early 
detection methods and interventions, are individuals more motivated to improve their 
health if they know they may be at a higher risk than the average population, and will 
individuals in the average-risk groups become complacent and therefore less likely to 
engage in healthy behaviors (Yoon et al, 2002).  
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Research literature suggests the presence of two epidemiologically distinct 
classifications of PrCa.  One group is characterized by earlier age at diagnosis and male-
to-male transmission and the other group has later age at diagnosis without the male-to-
male transmission (Cotter, Gern, Ho, Chang, & Burk, 2002).  The assessment of family 
history along with multigenerational pedigree analysis increases the likelihood of 
identification of multiple affected family members, early age onset, and identifications of 
patterns of inheritance that together can be used to identify men at high risk for familial 
or hereditary PrCa.  The men in these families with inherited predisposition to PrCa are 
candidates for initiation of PSA testing at least 5 years before the earliest age of diagnosis 
indicated in the pedigree (Bratt, 2006).  If the family history data indicates prostate 
related death or possible metastatic disease the men may need to start PSA screening 10 
years before the age at which metastatic disease appeared and no later than age 50 years 
(Bratt 2006).  The American Cancer Society recommends screening for men at high risk 
of PrCa from age 40 years or earlier.  To emphasize, assessment of the family history of 
all men with PrCa affords the chance for unaffected male relatives to be informed of their 
risk and seek relevant counseling including development of a plan of care.  Based on 
these recommendations, physicians are likely to encourage screening at age 40 for AfAm 
men (Bratt, 2006).  
Carter et al. (1992) found that 43% of hereditary PrCa was diagnosed before the 
age of 55 years but made up only 9% of all PrCa occurrences.  Compared to PSA testing 
in the general male population, testing men at high risk defined by family history can 
affect the cost-benefit ratio in a positive way.  The discovered incidence of multiple 
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affected family members decreases the number of men tested to locate one case of PrCa.  
More importantly, the positive predictive value of PSA is higher in men with positive 
family history leading to a smaller proportion of healthy men with false positive tests 
(Bratt, 2002).  
One study has found that awareness of family history is a motivator for improved 
screening uptake in men with a positive family history of PrCa (Bloom, Stewart, Oakley-
Girvans, Banks, & Chang, 2006).  Drake, Lathan, Okechucwu, & Bennett (2008) 
reviewed data from the National Health Interview Survey and found that among men 
with a family history of PrCa, AfAm men were more likely than EuAm men to have had 
a PSA test.  Their study also revealed AfAm men were screened more than EuAm men, 
but AfAm men with a family history did not receive more screening than AfAm men 
without a family history.   
Giovannucci, Liu, Platz, Stampfer, & Willet (2007) used data from the health 
professionals’ follow-up study (n=51,529), consisting of US male health professionals, 
ages 40-75 years.  This study identified the association of family history of PrCa with 
AfAm race tended to be stronger for both total and advanced PrCa in the pre- prostate 
specific antigen (PSA) PSA era.  Beebe-Dimmer et al. (2006) examined the association 
between family history of PrCa and breast cancer among AfAm men with PrCa.  They 
concluded a well-documented family history of all cancers among first-degree relatives 
may signal a need for more aggressive PrCa screening practices and the adoption of 
screening at an earlier age.  These researchers also emphasized the need to inform AfAm 
men of the significance of positive family history of breast and/or PrCa as a significant 
38 
 
PrCa risk factor, in addition to race.  Sharing a positive family history could have a 
substantial impact on the recommendations for surveillance, and disease prognosis.  
Likewise, AfAms should be encouraged to share news of their personal prostate and 
breast cancer diagnoses with relatives to allow their family members to make early 
informed decisions about cancer screening (Beebe–Dimmer, Drake, Dunn, Bock, Montie, 
& Cooney, 2006).   
A study by Madersbacher et al. (2010) examined the influence of family history 
on PrCa risk to determine the implications for clinical management.  They reported that 
five to ten percent of PrCa cases were caused by a dominant inherited susceptibility to the 
disease.  Autosomal recessive and X-linked modes of inheritance were also suggested.  
The study also reported a prediction that inherited genes (hereditary and familial PrCa) 
contribute 42% of the total risk of developing PrCa with unshared environmental factors 
(sporadic PrCa) making up the remaining 58% (Madersbacher, et al., 2010).  Given 
recent controversy over the positive predictive value of prostate-specific antigen (PSA), 
family cancer history is an underutilized predictive factor that can alter risk estimation for 
developing PrCa.  Through the use of basic patient questioning family history is a simple 
factor to assess in routine clinical practice and should be regarded as an important 
parameter to consider, next to PSA, for PrCa risk assessment (Madersbacher, et al., 
2010).  
 
Ethical, Legal and Social Issues 
 
 The ideology of genetic inheritance of PrCa or genetic predisposition to PrCa has 
implications for every person with a family history of the malignancy.  Social and 
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scientific researchers are just beginning to examine the ethical, legal, social aspects of 
genetic testing and genetic research, including family history and pedigree research.  The 
most prominent ethical issues related to family cancer history and pedigree research are 
associated with the potential for stigmatization, discrimination, privacy/confidentiality, 
and the social implications of risk labeling.  While the US Congress passed the Genetic 
Information Non-Discrimination Act (GINA) in 2008 to prevent these problems, these 
ethical issues may need to be addressed when working with vulnerable populations, such 
as AfAm men.  
AfAms are concerned about how their health information may be used to 
discriminate against them.  As briefly noted previously, AfAm may not be aware that 
GINA went into effect in 2009 (Steck & Eggert, 2011).  This law makes it illegal for 
health insurers or employers with more than 15 employees to discriminate against 
individuals based on genetic information.  Genetic information includes an individual or 
family member’s genetic tests, the occurrence of disease in family members, or the 
individual or family member’s participation in research that includes genetic testing, 
counseling, or education (Steck & Eggert, 2011).  Failure of researchers to consider and 
properly address these ethical issues may cause anxiety, impaired self-image, depression, 
and/or self-blame for participants providing the family history information.  
Unfortunately there were no studies that examine these ethical issues relative to PrCa.  
 Finally, researchers must be aware of the risk of discrimination and segregation 
associated with categorizing humans by “racial” and “ethnic” groups and press forward 
toward research to minimize the health disparity gap for diseases like PrCa in AfAms.  
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Though no sharp genetic boundaries can be drawn between human population groups, 
there are variations in frequency of certain polymorphisms and haplotypes within and 
among populations (Bonham, Warshauer-Baker, & Collins, 2005).  Discovery of such 
variations may help researchers and clinicians understand why AfAm men are 
disproportionately burdened with PrCa. 
 
Discussion 
 
 AfAm males have the highest overall incidence and mortality rate from cancer 
among all ethnic groups.  The mortality rate from PrCa is 2-5 times the level seen in other 
ethnic groups (Giuliano, et al., 2000).  Researchers and health care providers continue to 
search for an explanation for this persistent disparity.  The history of poor minority 
participation in clinical research and even poorer participation in genetics research 
hinders scientific discovery and further potentiates the burden of cancer for this 
population (Patel et al., 2010).   
 The result of this literature review guided by the ACCE model as described by 
Yoon et al. (2002) revealed that family cancer history data and pedigree analysis has been 
used in genetic research and is an analytically valid instrument for identifying men with 
hereditary PrCa and familial PrCa.  Clinically, there are many barriers to the collection of 
family health history data in AfAm populations such as lack of knowledge of family 
history, unwillingness to share family history, and inability to document family history 
due to limited literacy.  These barriers will have to be removed to adequately assess the 
clinical validity of family cancer history in the AfAm population.  It is possible that these 
cultural and societal barriers may decrease the clinical validity and clinical utility of 
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family cancer history assessment in the clinical and community healthcare settings.  
Therefore, there is a need for continued evaluation of the clinical validity and clinical 
utility of family cancer history information and pedigree analysis in AfAm men affected 
with PrCa.  There is also a critical need for additional research on the ethical, legal and 
social implications of the outcomes of family cancer history and pedigree research, such 
as the impact of being labeled high-risk based on ethnicity.   
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CHAPTER III 
 
MANUSCRIPT II:  PILOT TEST OF COMMUNITY-BASED FAMILY HISTORY 
TOOL AND PEDIGREE ANALYSIS TO PREDICT HEREDITARY PROSTATE 
CANCER 
 
 
Abstract 
 
Background 
 
 Family history as a risk factor for prostate cancer is well established; however, the 
risk is primarily based on samples from European and EuAm populations.  The family 
history questionnaire is the most commonly used predictive instrument for hereditary 
prostate cancer.  Early identification of hereditary prostate cancer in African-American 
men is critical in order to promptly treat the cancer and prevent possible metastasis and 
death.  Several publications report the use of a family history questionnaire but very few 
provide data related to the effectiveness of the tool.  The goal of this pilot study was to 
measure the use of a family history tool and pedigree analysis in a community setting to 
predict hereditary prostate cancer in African-American males. 
 
Methods 
 
The sample was identified through African-American churches in a rural southern 
state.  After consent, family history tool was used to collect family cancer history data 
from N=49 African-American men.  Pedigrees were diagrammed from the provided 
history data.  Exploratory analysis was performed to describe the sample relative to 
family history data.  Logistic regression was used to examine relationship between family 
history variables and the outcome of personal history of prostate cancer. 
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Results 
 
Age was the only detectable predictor of personal history of prostate cancer with a 
chi square (1, N=49) =6.755, p =.004. Twenty-two percent of the sample reported a 
personal history of PrCa (n=11).  The South Carolina Central Cancer Registry was able to 
confirm 56% of reported personal history of prostate cancer.  
 
Conclusions 
 
The comprehensive family history questionnaire and pedigree analysis was 
effective to identify hereditary prostate cancer.  Larger sample size and additional 
research are needed to further evaluate other predictors of hereditary prostate cancer in 
this vulnerable population. 
 
Introduction 
 
 Studies and epidemiological reports continue to reveal disparities in prostate 
cancer (PrCa) incidence and mortality between racial and ethnic groups.  African-
American (AfAm) men in South Carolina have a 55% higher incidence rate and a 35% 
higher mortality rate due to PrCa compared to European-American (EuAm) men (South 
Carolina Central Cancer Registry, 2008).  AfAm men in South Carolina have the highest 
age-adjusted death rate for PrCa in the nation (Drake et al., 2006).  The genetic 
predisposition of PrCa is well established and possibly the strongest among all common 
cancers (Lichenstein et al., 2000, Varghese, & Easton, 2010), but the role of 
genetics/genomics in the disproportionate incidence and mortality of PrCa in AfAm is not 
well established.  Inherited PrCa occurs at younger ages with a more aggressive 
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phenotype (Xu et al., 2010).  Bratt (2002) reported that men with a family history of PrCa 
are diagnosed, on average, six to seven years earlier than those without a positive family 
history.  The association with a positive family history is most likely caused by genetic 
mutations, linked with a higher risk of PrCa (Boyle, Severi, & Giles, 2003).  In Bratt’s 
study, it was noted that more than 40% of men diagnosed before age 55 may have a 
heritable etiology (2002).  Studies have determined that heredity plays a role in incidence 
of PrCa but the role of genetics/genomics in the disproportionate incidence and mortality 
of PrCa in AfAm is not well established (Ahaghotu et al., 2004; Bratt, 2006).  Given the 
higher incidence rates of PrCa, the migration of initial diagnosis at younger ages, and 
more aggressive disease at earlier ages some AfAm men from South Carolina may be 
affected with a hereditary form of the malignancy (Shibata & Whittemore, 1997; 
Mordukhovich, et al.,2011; Neider, Taneja, Zeegers, & Ostrer, 2003; Rennert, Zeigler-
Johnson, & Addya, 2011).  
The study of the role of genetics/genomics in PrCa in AfAm populations is 
hindered because this population is less likely than EuAm to have family cancer 
information documented in medical records.  In a study of race and gender disparities in 
hereditary colorectal cancer AfAms were found to have less knowledge of their paternal 
family history of cancer compared to EuAms (Kupfer, McCaffrey, & Kim, 2006).  This 
lack of family cancer history information may contribute to the health disparity of PrCa 
incidence and mortality as AfAms may not provide health care providers with the 
information needed to assess risk and guide healthcare decision-making.  The most 
commonly used instruments to study hereditary PrCa is a family history assessment tool 
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and pedigree construction with analysis but the validity and utility of any family history 
tool administered to a Southeastern AfAm population in a community setting is yet to be 
determined. 
 
Hypothesis and Specific Aims 
 
Prior to developing a study to examine the ability of the model to assess risk of 
hereditary PrCa in AfAm populations, it must first be determined if the model can 
identify AfAm families with hereditary PrCa.  Therefore, the purpose of this pilot study 
was to measure the feasibility to use the family history tool and the pedigree analysis 
portion of the model in a small sample of AfAm men.  
The specific aims for this study include the following: 
 
1) Identify families with hereditary PrCa. 
 
a) Use the Hopkins Criteria of hereditary PrCa as defined by Carter et al. 
(1992) and as utilized in genetic research of prostate cancer to identify 
pedigrees with obvious Mendelian patters of transmission of PrCa. 
 
b) Determine the proportion of self-reported personal PrCa history that can 
be confirmed through the SCCCR that will serve as a method of 
identifying PrCa cases. 
 
c) Identify the number of at risk individuals for each identified hereditary 
PrCa family 
 
 
2) Identify variables in the family cancer history tool that best predict 
hereditary PrCa.  
 
a) H0—There is no relationship between age and personal history of PrCa. 
 
b) H0—There is no relationship between having a father with PrCa and a 
personal history of PrCa. 
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c) H0—There is no relationship between having a father with any cancer 
and a personal history of PrCa. 
 
d) H0—There is no relationship between having a brother with PrCa and a 
personal history of PrCa. 
 
e) H0—There is no relationship between having a brother with any cancer 
and a personal history of PrCa. 
 
f) H0—There is no relationship between having a sister with breast cancer 
and a personal history of PrCa. 
 
g) H0—There is no relationship between having a mother with any cancer 
is and a personal history of PrCa. 
 
h) H0—There is no relationship between having multiple brothers with 
cancer and a personal history of PrCa. 
 
3) Evaluate the validity and utility of the family cancer history tool and 
pedigree analysis of hereditary PrCa as used in a subset of the southeastern 
AfAm men.  The family cancer risk assessment model as evaluated using 
statistical analysis of family cancer history data and pedigree analysis will 
find significant correlation between known family history variables (age, 
brother with cancer, father with cancer, multiple affected first degree 
relatives.)  
 
a) H0—There is no relationship between known predictor variables of 
hereditary PrCa and personal history of PrCa. 
 
b) H0— There is no relationship between confounding variables (education, 
health insurance, time spent outside during daytime hours) and a 
personal history of PrCa.  
 
Materials and Methods 
 
 The Investigational Review Board (IRB) of Clemson University provided 
approval for, Discovering HIStory:  Using Family History to Discover the Genetic 
Predisposition for Prostate Cancer in African American Men.  Because the family history 
tool was administered in a community setting the investigator needed a way to confirm 
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personal history of PrCa so an application was also submitted to and accepted by the 
South Carolina Central Cancer Registry (SCCR) to validate the participant’s report of 
personal history of PrCa.  Participants that documented a personal history of PrCa 
completed an Authorization for Release of Protected Health Information Form (see 
Appendix F). 
A non-experimental, descriptive, correlational design was used for this pilot 
study.  The most commonly reported approaches to successful recruiting of AfAm 
participants as research subjects include community outreach through the church, 
barbershop, civic organizations, and physician referral (Mastalski, Coups, Ruth, Raysor, 
& Giri, 2008; Royal et al., 2000).  Multiple approaches were used to gain access to the 
AfAm churches in two rural South Carolina counties with limited results.  Two separate 
letters were mailed to the ministers of two AfAm Baptist Associations requesting their 
support of the PrCa research by allowing the investigator to provide an educational 
presentation on the role of family history in health promotion and cancer prevention at 
churches in their respective associations.  Contact was also made with the moderators of 
each association to schedule a day and time to talk with the ministers and church leaders.  
Seven of eleven ministers contacted agreed to support the presentation to their respective 
congregations (see Table 3.1 and Appendix C). 
To increase awareness and introduce the importance of family history, a 
presentation titled “Discovering HIStory” was developed.  This thirty-minute PowerPoint 
presentation included information on the role of family history in assessing individual 
risk of cancer, provided resources for documenting family health history and discussed  
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Table 3.1.  Participating Churches. 
 
 
 
 
 
 
Church 
 
 
 
 
 
Date 
 
 
Males in 
Attendance 
(Packets 
Distributed) 
 
 
 
 
Histories 
Collected 
 
 
 
Personal 
History of 
PrCa 
 
 
 
PrCa 
Report 
Confirmed 
History 
Packets 
Not 
Returned 
or 
Completed 
 
Packet 
Incomplete 
(Data Not 
Included In 
Analysis) 
1 10/26/11 13 3 0 NA 10 0 
2 4/1/12 25 7 1  14 4 
3 4/15/12 15 1 0 NA 14 0 
4 3/18/12 23 5 2  17 1 
5 3/25/12 10 6 3  4 0 
6 2/19/12 
thru 
2/24/12 
13 13 4  0 0 
7 2/5/12 22 12 0 NA 10 0 
8 4/8/12 54 4 3  50 0 
Total  175 51 13  119 5 
 
Male attendance at each church workshop and the number of family history tools 
distributed and returned. 
 
lifestyle modifications including diet, exercise, and cancer screening.  Attendees were 
given American Cancer Society brochures on breast, prostate and colon cancer.  
Attendees also received a copy of a brochure developed by the investigator using a 
template from the Genetic Alliance web site, titled Does It Run in the Family?  A Guide 
to Family Health History (see Appendix I).  The full 30-minute presentation was 
presented at three of the eight AfAm churches.  Abbreviated presentations were provided 
at the remaining five churches following requests to minimize disruption of Sunday 
morning worship service.  The educational session was not part of the proposed research 
and did not require IRB approval (see Figure 3.1). 
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Figure 3.1.  Education Program and Family History Study Model. 
 
 
 
Men and women attended the Discovering HIStory Education Program.  The men that 
were interested in participating in the study remained after the program and after consent 
was provided completed a family history tool and demographic form.  Family pedigrees 
were later developed from the information provided on the family history tool. 
 
 
Study Population 
 
 The desired study population was AfAm males’ ages 18-80 years that attended 
AfAm Baptist and Methodist churches in two rural counties of South Carolina.   
 
Data Collection 
 
The study was presented at the end of the educational presentation.  To minimize 
coercion and provide confidentiality, interested participants were invited to meet with the 
investigator in a designated private room after the presentation to document their family 
cancer history for use in the study.  Once in the private room, the men were given the 
consent form describing the risk, benefits, and their rights as participants in the study.  
54 
 
The form was read to those individuals that indicated a literacy problem.  After reviewing 
the consent form, questions were addressed and answered.  Upon signing the consent 
form, the participants were given the family cancer history tool, which they completed 
and returned to the investigator for review.  When needed, the investigator read the tool 
to participants and documented their responses.  If the participant documented a personal 
history of PrCa, the phenotype of interest, the participant was asked to complete an 
additional form giving the researcher permission to confirm PrCa diagnosis through the 
South Carolina Central Cancer Registry.  The family cancer history tool, demographic 
form, and consent form were labeled with participant ID numbers.  Each participant was 
given an 8” x 11” envelope and asked to seal their information in the envelope.  The 
envelopes were collected by the investigator and remained in the procession of the 
investigator after leaving the community site.  Upon return to a secure location the 
information was removed from the envelope and the consent forms and release forms 
were secured in a locked file cabinet.  
 
Family Cancer History Tool 
 
The family cancer history tool was designed for self-administration.  The tool 
consisted of a series of tables designed to elicit information to construct a three-
generation pedigree.  Information on some first cousins (third-degree relatives) was 
obtained but no information was gathered on great aunts/uncles or great grandparents.  
For each relative, the table included a place to provide age or age at death, cause of death, 
type of cancer(s) diagnosis, and age at cancer diagnosis.  To elicit the size of the family, a 
separate table was provided where relatives could be listed, and an area to explain the 
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exact relationship to the participant.  Space was also provided to indicate if the 
participant had children with more than one partner or if the individual had half siblings.  
This tool, adapted from a family history questionnaire published as part of a study of 
family history in hereditary breast and ovarian cancer, can be viewed in Appendix A 
(Armel et al., 2009).  
In the hereditary cancer clinics, family history tools are used to triage patients for 
genetic counseling and genetic testing.  Armel et al. (2009) noted that in Ontario, Canada, 
approximately 60% of hereditary cancer clinics in Ontario, Canada, used family history 
tools in spite of the absence of evidence-based data related to their effectiveness.  Their 
study assessed the efficacy of the family history tool in use by one hereditary breast and 
ovarian cancer clinic, the results supported that a family history tool is an effective tool 
for assessing genetic testing eligibility.  Similar to this pilot study, Armel et al. (2009) 
used pedigrees developed from family history data, but explored the effectiveness of the 
family history tool by comparing the pedigrees created from the tool to pedigrees updated 
during genetic counseling.  Results from the findings supported the modification of the 
family history tool (Armel et al., 2009).  The published copy, used in this study is 
provided as Appendix B. 
 
Definitions of Variables 
 
 Personal history of PrCa was the outcome variable.  The main exposure variable, 
family history of cancers, was defined as self-reported history of any cancer with a 
special query for prostate and breast cancer among first-degree relatives including 
parents, siblings, and offspring.  Age was a continuous variable and recorded as number 
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of years.  Other covariates included education, health insurance, and sun exposure.  The 
variables of occupation, height, weight, though assessed on the demographic, were not 
included in the data analysis due to inconsistent provision of information by participants.  
A final question on the demographic form asked if the participant would be willing to 
provide a buccal specimen as part of future research studies.  This question was included 
to assess the percentage of AfAm men willing to provide a buccal specimen in future 
research of PrCa. 
 
Statistical Analysis 
 
An exploratory analysis was done to examine the characteristics of the study 
participants.  This involved consideration of the frequency of the categorical variables 
and descriptive statistics such as the mean, range, standard deviation, and skew of the 
continuous variables. 
A Chi square (χ2) test examined the association between incidence of PrCa and 
other categorical variables.  The likelihood ratio statistic was used because it is more 
robust when a small sample size results in small-expected cell counts.  Logistic 
regression was used to examine association between incidence of PrCa and continuous 
variables, and to examine how certain combinations of two independent variables impact 
PrCa incidence.  When examining the impact of two independent variables the 
Likelihood ratio Chi-square (χ2) test was used to determine if there was any significant 
variable in the model.  Finally, the Likelihood ratio Chi-square (χ2) statistic was used to 
determine which specific variables were related to the odds of having PrCa.  No power 
analysis was performed to project sample size prior to this pilot study.  The level of 
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significance was p= 0.05, as this was commonly used in similar studies.  All analyses 
were conducted using Statistical Package for the Social Science (SPSS®) version 17.0 
(SPSS, Inc., Chicago, IL). 
 
Results 
 
 The purpose of this study was to pilot the proposed family history tool in a 
community setting as a possible intervention method to identify AfAm men with 
hereditary PrCa.  The study sample (N=49) reflected an average subject age of 57 years 
(range 36-79 years; S.D. 11.983).  The majority of the men had health insurance and a 
primary healthcare provider (91.7%, 81.6%).  None of the men reported achieving less 
than a high school education, 27.5% completed high school, 37.3% attended college, and 
35.2% completed college.  Table 3.2 provided the demographics of this pilot study.  
 Twenty-two percent (22%) of the AfAm men sampled had a personal history of 
PrCa (see Table 3.3).  Eleven participants reported a personal history of PrCa.  Eight of 
the eleven (72%) reported no family history of PrCa.  Three of the eleven (27%) reported 
having brother(s) with PrCa.  None of the eleven participants with a personal history of 
PrCa reported having a father with PrCa.  The Likelihood ratio (LR) for having a 
personal history of PrCa given he has a brother with PrCa was 2.89 (p = 0.089).  The LR 
of having a personal history of PrCa given you have multiple brothers with PrCa is 6.71 
(p = 0.082).  Age was the only variable found to be significantly related to the incidence 
of PrCa Likelihood ratio chi-square (χ2) (1, N = 49) = 10.193, p =0.001 (See Tables 3.4-
3.6).  The mean age at diagnosis was 62 years (S.D. 7.54).  Table 3.3 shows the reported 
family history of cancer.  The variables daytime hours spent outside, having health  
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Table 3.2.  Participant Demographics. 
 
Characteristics Number Percentage 
Males 49 100% 
Mean age (range) 57 (36-79)  
Age at diagnosis (range) 61 (53-79)  
Health Insurance 41 (3 missing) 91.7% 
Education 14 Completed HS 
18 Some College 
17 Completed College 
27.5%  
37.3%  
35.2  
 
Average age for pilot sample (N = 49).  Age at diagnosis for participants that reported a 
personal history of PrCa.  Number and percentage of participants with health insurance. 
Level of education as reported by each participant. 
 
 
Table 3.3.  Percentage of Sample Reporting Family History of Cancer. 
 
Family History Number Percentage 
Personal History of PrCa 11 22% 
Mother with cancer 9 18% 
Father with Cancer 9 18% 
Father with PrCa 5 10% 
Brother with Cancer (other than PrCa) 1 brother- 5 10% 
Brother with PrCa 1 brother-1 
2 brothers- 1 
3 brothers - 1 
2% 
2% 
2% 
Sister with Cancer (other than breast cancer) 1 sister -4 
2 sisters- 1 
8% 
2% 
Sister with Breast Cancer 1 sister- 4 8% 
 
Proportion of the participants (n=49) with a family history of cancer.  For example, 4 of 
the participants had 1 sister with cancer and 1 participant had 2 sisters with cancer. 
 
 
Table 3.4.  Chi-Square (χ2) and p-values for age (continuous) predictor variable. 
 
Variable Likelihood Ratio Chi-
Square (χ2) 
df N p-val 
Age 10.193 1 49 .001 
 
Note. p<0.05. Age was found to be significant,  LR (χ2) (1, N = 49) = 10.193, p =0.001 
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Table 3.5.  Chi-Square (χ2) and p-values for each (categorical) predictor variable. 
 
Variable Likelihood Ratio df N p-val 
Education 0.666 2 49 .717 
Primary MD 0.000 1 49 .986 
Health Insurance 1.131 1 49 .288 
Inside/Outside 0.565 1 49 .452 
Mother_Ca 0.922 1 49 .337 
Father _Ca 0.922 1 49 .337 
Father _PrCa 2.703 1 49 .100 
MGM_Ca 1.581 1 49 .804 
MGF_Ca 0.199 1 49 .655 
PGM_Ca 1.041 1 49 .308 
PGF_Ca 0.514 2 49 .473 
Num Br_Ca 5.546 2 49 .062 
Br_PrCa 2.892 1 49 .089 
Num_Br_PrCa 6.711 3 49 .082 
Num_S_BrCa 0.016 1 49 .900 
Num_MA_Ca 1.795 2 49 .408 
Num_PA_Ca 0.514 1 49 .473 
Num_ PU_Ca 0.542 2 49 .763 
Num_MU_Ca 1.460 3 49 .692 
     
 
Note:  p<0.05. Direct logistic regression for each predictor variable of the family history 
revealed a likelihood ratio.  None of the predictors significantly predicted a personal 
history of PrCa.  Brothers with PrCa, having a brother with PrCa and Number of brothers 
with any cancer approached significance.  
 
Key—CA-cancer, MGM-maternal grandmother, MGF-maternal grandfather, PGM-
paternal grandmother, PGF-paternal grandfather, Num- number, Br- Brothers, PrCa-
prostate cancer, BrCa-breast cancer, PU-paternal uncles, PA- paternal aunts, MU-
maternal uncles, MA-maternal aunts, MD-medical doctor. 
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Table 3.6.  Regression analysis for select predictor variables. 
 
Variables Likelihood 
Ratio (χ2) 
Omnibus test 
p-val Sub variable Likelihood 
Ratio (χ2) 
p-val 
Age 10.193 .001 Age 6.755 0.009 
 
Age_Education 
 
10.476 
 
.015 
 
Age 
 
9.810 
 
0.002 
   Education 0.283 0.868 
 
Age_Num_S_Ca 
 
12.908 
 
.005 
 
Age 
 
12.383 
 
0.000 
   Num_S_Ca  2.715 0.257 
 
Age_ Num_Br_PrCa 
 
14.436 
 
.006 
 
Age 
 
7.725 
 
 0.005 
   Num_Br_PrCa 4.243 0.236 
 
Age_Father_PrCa 
 
13.589 
 
.001 
 
Age 
 
10.886 
 
0.001 
   Father_PrCa 3.396 0.065 
 
Age_Inside/Outside 
 
12.820 
 
.002 
 
Age 
 
12.255 
 
0.000 
   Inside/Outside 2.627 0.105 
 
Age _Age at Dx 
 
.000 
 
1.00 
 
Age 
 
0.000 
 
0.993 
   Age at Dx 0.000 0.993 
 
Age_Primary MD 
 
10.342 
 
.006 
 
Age 
 
10.342 
 
0.001 
   Primary MD 0.150 0.699 
 
Note:  p< 0.05.  The Likelihood Ratio statistic of the Omnibus test and the respective p-
value were used to determine whether two predictor variables when placed in the 
regression model as main effects were significant.  If the omnibus test was significant 
then the Test of Model Effects was considered to see which of the two variables (sub 
variables) contributed to the outcome = personal history of PrCa.  In every model age was 
the significant predictor variable. 
 
Key:  Ca—cancer, Dx—diagnosis, Num—number, MD— medical doctor. 
 
 
insurance, level of education, having a mother with cancer, having a sister with cancer, 
having a sister with breast cancer, having a brother with PrCa and having a father with 
cancer, and having a father with PrCa were not found to be significant at an alpha of 0.05. 
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Discussion 
 
The following discussion is guided by the specific aims of the pilot study.  
Specific aim one was to identify families with hereditary PrCa.  The Hopkins Criteria of 
hereditary PrCa as defined by Carter et al. (1992) was utilized to identify pedigrees with 
obvious Mendelian patterns of transmission of PrCa.  There was one participant who met 
the criteria for hereditary PrCa; with three affected brothers and one affected paternal 
uncle.  Another participant was diagnosed with PrCa at the age of 53 years, but did not 
report having any other family members affected with PrCa.  Early onset, < 55 years of 
age, is a criterion for hereditary PrCa; but, there must be at least two affected relatives 
under the age of 55 years (Carter, et al., 1992).  
An additional objective of specific aim one was to determine the proportion of 
self-reported personal PrCa history that can be confirmed through the SCCCR that will 
serve as a method of identifying PrCa cases.  Thirteen participants reported a personal 
history of prostate cancer.  Only eleven of the participants’ family history and pedigree 
information were included in the statistical analysis.  As reported earlier, three of the 
participants were brothers and though all three had a personal history of prostate cancer 
only one brother’s family history data was included in the analysis.  Seven participants 
provided authorization for release of health information.  Four or the seven (57%) 
personal histories were linked positively to the SCCCR database.  The SCCCR database 
contains prostate cancer history from 1996-2009.  The family history tool asked for age 
of diagnosis, whether the participant lived in South Carolina at the time of diagnosis, city 
and county of diagnosis, did the diagnosing physician practice in South Carolina, and the 
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name of the physician.  But on the authorization form used by SCCCR to search the 
database only the full name, date of birth, address, and phone number are provided.  
Additional information from the demographic portion of the tool, such as name of 
diagnosing physician, name of physician that treated prostate cancer, and if physician that 
diagnosed the PrCa practice in South Carolina should be added to the authorization form 
to aide with linkage.  Space to document the year of diagnosis beside the age at diagnosis 
will also facilitate linkage in the SCCCR database.  
The final objective of specific aim one was to identify the number of at risk 
individuals for each identified hereditary PrCa family.  The only hereditary PrCa family 
has a total of 26 males.  The pedigree suggests that a variant genotype predisposing to 
hereditary PrCa is possibly in the paternal lineage, therefore there are 13 possible male 
carriers of the variant genotype.  Five of the thirteen males are deceased, four have the 
phenotype (PrCa) and are living, and four do not have the phenotype.  At the time of the 
assessment 30% of the males in this family are affected and 30% are at very high risk.  
The relative risk of the participant’s unaffected brother for developing PrCa by the age of 
70 is 35.23 (95% CI: 27.74, 44.62).  The relative risk for the participant’s son and 
nephews for developing PrCa by the age of 60, considering all of their fathers developed 
PrCa by the age of 60 years, is 11.99 (95% CI: 9.4, 15.18) and by age of 70 years their 
relative risk is 35.23 (95% CI: 27.74, 44.62) (Nieder, Taneja, & Zeegers, 2003).  
Specific aim two was to identify variables in the family cancer history tool that 
best predict hereditary PrCa.  Known predictors of hereditary PrCa are three or more 
first-degree relatives with PrCa, relatives with PrCa in three successive generations of 
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either the maternal or paternal lineage or at least two relatives diagnosed with PrCa 
before the age of 55 years.  Age was the only statistically significant predictor of personal 
history of PrCa.  None of the individuals in the hereditary prostate cancer family were 
diagnosed before the age of 55 years.  There was only one participant that reported being 
diagnosed with PrCa younger than 55 years, he was 53 years of age at diagnosis, but he 
had no other family history of PrCa.  Due to the small sample size and the selected 
statistical analysis method it was not possible to reject the null hypothesis (b-h) 
previously noted for specific aim two.  It is worth noting that the predictor variables 
brother with PrCa and number of brothers with PrCa approached statistical significance at 
LR 2.89 (p = 0.089) and 6.71 (p = 0.082), respectively. 
The third specific aim was to evaluate the validity and utility of the family cancer 
history tool and pedigree analysis of hereditary PrCa as used in a pilot sample of the 
southeastern AfAm men.  Due to the small sample, only one hereditary PrCa family was 
identified and the statistical analysis method of logistic regression instead of multinomial 
regression, the study failed to reject the null hypothesis that there is no relationship 
between known predictor variables of hereditary prostate cancer as defined by Carter et 
al. (1992) (early age onset, multiple affected first-degree relatives i.e., brothers, sons, and 
a father).  The study was unable to reject the null hypothesis that there is no relationship 
between the confounding variables and hereditary prostate cancer. Statistically rejecting 
the null hypothesis would have favorably impacted the analytical validity of the piloted 
risk assessment model.  
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Conclusion 
 
This study showed that age, even in this small sample, is a strong predictor of 
PrCa.  It also found that the piloted family history tool and pedigree analysis method has 
marginal analytical validity.  According to the National Cancer Institute (2011), 5-10% of 
the total cases of PrCa in the general population are hereditary PrCa.  Therefore, it was 
expected that out of 11 cases of PrCa there would be one case of hereditary PrCa.  In this 
study sample of 11 cases, one participant met the criteria for hereditary PrCa.  One of the 
most promising findings of this study is the similar age related incidence, regardless of 
the small sample size (see Figures 3.2 and 3.3).  The nearly parallel alignment of the age 
related incidence potentially indicates that the selected rural southern population is 
affected with PrCa in a manner that closely mimics that of the rest of the state and nation.  
The process of designing this study has equipped this novice researcher with the 
experience and knowledge to improve the study design, statistical analysis methods and 
recruitment in future studies.  The investigator plans to modify the family history tool and 
continue to pilot it in a public health setting to evaluate and improve the analytical 
validity.    
 
Implications for Translational Research 
 
The purpose of this study was to pilot the proposed family history tool in a 
community setting as a possible intervention method to identify AfAm men with 
hereditary PrCa.  Using the four domains of the ACCE model as published by Yoon et al. 
(2003), for evaluating family history as a predictive and risk assessment tool this study 
starts to examine the element of analytic validity of a specific family history tool and  
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SPSS table presents the number of participants (vertical axis) for each age (horizontal 
axis). Count = number of participants. Green bars= participant reported a personal history 
of PrCa. Blue bars = participant did not report a personal history of PrCa. Illustrates the 
age at diagnosis for those with a personal history of PrCa tends to be in the lower half of 
the table, which is consistent with prostate cancer being a disease that affects older men. 
 
Figure 3.2.  Personal History of PrCa. 
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Comparison of the percentage of individuals diagnosed within each age group for the 
Discovering HIStory pilot sample against that reported for national SEER data and the 
state cancer registry.  Though the sample size was relatively small for the study the data 
is comparable to that of the national and state populations of AfAms. 
 
Figure 3.3.  National (SEER), State (SCCCR), Discovering History Comparison of Age 
at Diagnosis. 
 
 
pedigree analysis model.  In this particular study analytic validity indicates how well the 
family history tool and pedigree analysis identifies and measures hereditary PrCa.  
Kerber & Slaterry (1997) & Zioags et al. (2003) found the proband’s report of cancer 
among affected relatives demonstrates a high degree of accuracy for PrCa.  Accurate 
family history data lends to the validity of the family history tool as an assessment 
instrument.  This study did not attempt to verify disease status of relatives of the 
participant, but for the participant who reported a personal history of PrCa it was 
concluded that 56% had verifiable cases of PrCa through the South Carolina Central 
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Cancer Registry (SCCCR).  More importantly the ability of the SCCCR to be able to link 
to the limited data and confirm four of the seven cases is encouraging.  In future 
investigation of the model, with a larger community based sample, the SCCCR will serve 
as the “gold standard” for confirming cases of PrCa.   
Validating the personal history of the participant was the first step in assessing the 
analytical validity of a tool designed for use in a clinical setting.  Had the research been 
conducted in a clinical setting the investigator would have access to medical records as 
method of confirming the participant’ health status.  Future research is needed to evaluate 
the remaining domains of the ACCE model, clinical validity, clinical utility, and ethical, 
legal, and social implications.  
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CHAPTER IV 
 
MANUSCRIPT III:  USE OF FAMILY HISTORY AND PEDIGREE IN PUBLIC 
HEALTH NURSING TO IDENTIFY AFRICAN-AMERICAN MEN AT RISK FOR 
HEREDITARY PROSTATE CANCER:  CASE REPORT 
 
 
Abstract 
 
One goal of Health People 2020 is to” improve health and prevent harm through 
valid and useful genomic tools in clinical and public health practices.”  Prostate cancer is 
a public health problem with a disproportionate impact in African-American populations.  
Higher incidences of prostate cancer migration towards earlier ages, and more aggressive 
disease at younger ages in African-American imply a genetic predisposition to the 
malignancy.  Implementation of initial screening and health promotion measures earlier 
in the lives of African-American men, who are at exceedingly high risk due to ethnicity 
and hereditary factors, needs to be established as a national guideline much like women 
in families with hereditary breast cancer.  Increasing scientific evidence supports the 
health benefits of using family health history tools to guide clinical and public health 
interventions.  This case report demonstrates how a comprehensive family health history 
questionnaire and the resulting pedigree can be used as a public health nursing 
intervention to identify AfAm men at risk for hereditary prostate cancer.  The manuscript 
illustrates how knowledge of family history can be used to identify unaffected at-risk 
males and serve as a stimulus for community based educational programs.  Such 
programs can be designed to decrease the health disparity of prostate prostate cancer in 
African-American communities by empowering men with the information to decrease 
fear and anxiety while promoting health and preventing disease.    
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Introduction 
 
Prostate cancer is a major worldwide public health problem.  As many as one in 
six men in the US will be affected with prostate cancer (PrCa) (Howlander, et al., 2012).  
Estimated worldwide incidence annually is 899,000 new cases per year with, 186,320 per 
year in the US (Globocan, 2008).  Approximately 5-10% (44, 950 to 89,900 cases 
worldwide and 9,316 to 18,632 cases in the US) of the total PrCa burden follows a 
Mendelian inheritance pattern (Carter et al., 1993).  Researchers continue to search for 
causative germ-line mutations.  In the US, African-American (AfAm) men have an 
estimated annual PrCa incidence of 250,000 cases (CDC, 2012).  If the 5-10% proportion 
of hereditary PrCa holds true for AfAm men, approximately 12,500 to 25,000 men are 
affected with hereditary PrCa.  The higher incidence of PrCa, the migrations toward 
earlier ages, and more aggressive disease at younger ages in AfAm imply a genetic 
predisposition to the malignancy.  Therefore, implementation of earlier screening 
protocols of AfAm men, who are at exceedingly high risk as a result of ethnicity and 
hereditary factors, are strongly recommended.  The challenge then becomes the 
identification of AfAm men at risk for developing hereditary PrCa.  This manuscript 
proposes the use of a comprehensive family cancer history tool and pedigree analyses as 
a cost efficient method for public health nurses to identify AfAm men at extremely high 
risk for PrCa.  A case report is used to demonstrate how data from a comprehensive 
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family cancer history tool is translated into a multigenerational pedigree for easy 
recognition of hereditary PrCa. 
Following the suggestions of Yoon, Scheuner, & Khoury, (2003) a simple, easily 
applied, and inexpensive public health-oriented, family history tool designed for use in 
diverse populations was used for collection of information.  Though simple, the tool 
allowed for collection of enough information to make prediction possible; therefore, 
facilitating the classification of individuals into different risk groups (Yoon, Scheuner, & 
Khoury, 2003).   
 
Case Report 
 
In a pilot study of a family cancer history questionnaire, AfAm men (N=49) 
provided family cancer history data transmitted into pedigrees and analyzed to determine 
factors that best predict familial and hereditary PrCa.  Of the 49 histories, only one family 
met the criteria of hereditary PrCa.  Three of five male siblings attended the Discovering 
HIStory educational program and each completed a family history questionnaire.  One of 
the brothers had a family history questionnaire used in the study, but the respective 
family cancer histories corroborated the history provided by the participating brother.  
Characteristics of the pedigree are described below.  All medical history was self-
reported and permission to share information within the family unit was obtained prior to 
disclosure.  
In the case study, four brothers and a paternal uncle were affected with PrCa; 
therefore, meeting the Hopkins Criteria (Carter, Beaty, Steinberg, Childs, & Walsh, 
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1992); three or more affected first-degree relatives (father, brother, son).  Figure 4.1 
shows the pedigree as of May 2012. 
The consultand, indicated on pedigree in position III.2, sought medical attention 
for difficult urination.  Consultand III.2 reported prostate-specific antigen (PSA) of 8 
mg/dL (Reference range 0-4ng/dL) upon consultation with a primary care provider.  
Prostate biopsy confirmed PrCa, which was initially treated in 2003 with cryosurgery.  
Increasing PSA levels in 2009, prompted additional cryosurgery, with confirmation of 
aggressive PrCa diagnosis.  The consultand was not a candidate for prostatectomy due to 
obesity and other comorbidities, so hormone ablation was performed in 2010.  
Relative III.3, now 67 years of age, was diagnosed with PrCa at 55 years of age.  
He presented to primary care provider with problems urinating:  “I always felt like I had 
to go, but even after I went I still felt like I had to go.”  PSA at the time of diagnosis was 
4.5 ng/dL.  No additional details of his medical work-up were provided, but reported 
treatment with successful results.  
Relative III.8, the youngest of the brothers, was diagnosed with PrCa during a 
routine annual examination.  No symptoms were reported and PrCa was only detected 
with an elevated PSA; the exact PSA level was unavailable with recall.  Age at diagnosis 
57 years and treatment was seed radiation.  He continues to see his doctor regularly, and 
reports his last “check-up” was “good.” 
 The three brothers all reported there is an older brother, relative III.1. who was 
recently diagnosed with PrCa. Due to his advanced age (71 years), other health issues, 
and the recommendation of his doctor, treatment for PrCa has not been initiated.  One  
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Figure 4.1.  Hereditary Prostate Cancer Pedigree. 
 
 
paternal uncle was also reported to be diagnosed with PrCa.  It was also noted the father 
of the brothers died at age 30 in an accident (See Figure 4.1). 
 
Discussion 
 
 Public health nurses monitor health trends and identify health risk factors unique 
to specific communities.  They set local priorities for health-related interventions to 
provide the greatest benefit to the most people, design and implement health education 
campaigns and disease prevention activities, educate communities regarding locally 
available health care programs and services to improve access to care, and educate and 
provide direct health care services to vulnerable and at-risk populations (American 
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Nurses Association, 2007).  It is known that PrCa is a public health problem that has a 
disproportionate impact in AfAm populations.  In Healthy People 2020, a health disparity 
is defined as:  
 
A particular type of health difference that is closely linked with social, 
economic, and/or environment disadvantage.  Health disparities adversely 
affect groups of people who have systematically experienced greater 
obstacles to health based on but not limited to their racial or ethnic groups, 
socioeconomic status; gender; age, cognitive ability, physical ability, 
geographic location or other characteristics historically linked to 
discrimination or exclusion.  (US Department of Health and Human 
Services, 2010, “The Future Genomics in Public Health”).  
 
 
While not considered a genetic test, but used in surveillance of prostate cancer, 
the US Preventive Service Task Force (USPSTF) recently rendered a recommendation 
grade of “D” for PSA screening.  The final recommendation grade of “D” indicates that 
the USPSTF is against the use of PSA screening for PrCa (Moyer, 2012).  Without a 
diagnostic or predictive genetic test for PrCa and major debate over the benefit of PSA 
screening, healthcare providers will need to rely more than ever on a complete family 
health history.   
There is some research on the validity and utility of family health history tools in 
clinical settings of clinical research and primary care, but there is a marked deficit of 
research in the validity and utility of family health history tools in public health settings 
and as a public health intervention.  In an effort to accomplish the goal to improve health 
and prevent harm through valid and useful genomic tools in clinical and public health, 
Health People 2020 proposes specific objectives involving family history and genetic 
test.  The specific objectives are included Table 4.1.  
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Table 4.1.  Healthy People 2020 Objectives Related to Family History and Genetic Test. 
 
1. Creating and evaluating scientific evidence to support valid and useful genetic test 
and family health history tools; 
  
2. Developing evidence-based practice recommendations that evaluate the net health 
benefit of genetic tests and family health history tools; 
  
3. Conducting research on how to translate recommendations into practice; 
  
4. Facilitating the use of valid and useful family health history tools to guide clinical 
practice, policy, and national, State, and local programs to find people who are at 
risk for disease, make diagnoses, and provide appropriate interventions;  
  
5. Monitoring the use of genetic tests and family health history in populations, the 
health outcomes related to their use, and disparities in use and outcomes; and 
  
6. Improving health and prevent harm through valid and useful genomic tools in 
clinical and public health practices (US Department of Health and Human 
Services, 2012). 
 
Table adapted from US Department of Health and Human Services (2012).  Healthy 
People.gov.  Retrieved from http://www.healthypeople.gov/2020/default.aspx. 
 
 
This case report stems from a pilot study of a family cancer history tool and 
pedigree analysis used as a part of community health education program.  The pilot study 
was designed to address objectives three and four Healthy People 2020.  Family cancer 
history tools and pedigree analysis are used in genetic/genomic research to identify 
hereditary PrCa families; the aforementioned pilot study examined the effectiveness of a 
research method as a public health intervention.  More importantly this pilot study was 
the first step in validating a family cancer history tool for use in public health settings to 
help AfAm men recognize their risk of PrCa and to assist public health nurses identifying 
high risk individuals who may benefit from targeted health promotion and early screening 
efforts. 
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Implications for Nursing Practice 
 
 All three of the brothers were managed medically for their respective PrCa, but 
the implication for the public health nurse comes with the knowledge there are four males 
(1 male in generation III and 3 males in generation IV) who may benefit from targeted, 
early screening and health promotion.  The health promotion efforts should include 
education targeting these at-risk males.  The educational materials need to incorporate 
information of risk factors for PrCa including genetics, race/ethnicity, family history, age, 
diet, obesity, and chronic inflammation.  To obtain the greatest impact the nurse should 
encourage the at-risk males to share the materials and information with first and second-
degree young-adult male relatives.  The following content summarizes the current body 
of evidence related to the utilization of family history in the study of genetic and 
environmental risk factors of PrCa.  The studies selected for this manuscript were 
conducted in the US since the completion of the Human Genome Map in 2003 and 
examined risk factors of PrCa.  
 
Inherited Genetic Risk Factors 
 
 With the completion of the Human Genome Map in 2003 and continued advances 
in technology linkage analysis and genome-wide association, research continues to 
examine and evaluate the hypotheses generated by aggregation and segregation analysis 
of prostate cancer.  The following synopsis of literature summarizes some of the known 
genetic risk factors of PrCa, a very complex, polygenic disease.  
Xu et al. (2005) conducted a genome-wide linkage scan of families (N=1,233) 
with PrCa.  In the first analysis of all families, researchers found no significant evidence 
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of linkage in the total genome.  However, evidence of suggestive PrCa linkage was 
observed at five chromosomal regions on the long arms (q) of the chromosomes 5, 8, 15, 
17 and 22 at different loci (5q12, 8p21, 15q11, 17q21, and 22q12).   
Families were further divided into subsets (n=269) to determine if genes were 
more likely to segregate in families with stronger family PrCa risk; families with at least 
five affected members or with family mean age at diagnosis of < 65 years.  Those with a 
stronger family PrCa risk demonstrated stronger evidence of linkage in the six regions.  
Two (17q21 and 22q12) were noted in the original analyses and four in new regions.   
Among this subset of families, at least five had affected members with linkage in six 
regions, two, 17q21 and 22q12, previously identified in the primary analysis of the entire 
set of families.  
The secondary analysis of the subset of families with mean age at diagnosis of < 
65 years (n=606) revealed evidence of linkage in four regions on both the short (p) and 
long arms (q) of chromosomes 3, 5, 11 and X; specifically loci 3p24, 5q35, 11q22, and 
Xq12.  None of these regions were found in the previous two analyses.  Currently, these 
regions only suggest possible locale of major PrCa susceptibility genes (Xu et al., 2005). 
 Many chromosomes have been linked to hereditary PrCa, though none with a 
specific causative variant.  One study identified multiple regions of suggestive 
chromosomal linkage by stratifying EuAm families according to age at PrCa diagnosis 
and number of affected men within each family.  Similar methods of genome-wide 
scanning detected three distinct chromosomal loci at 11q25, 15q26, and 17p12.  Even 
families with a weak familial history of PrCa had loci detected at chromosome regions 
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7q21, 8q22, 15q13-14, and 2q21.  These were totally distinct from those located by Xu et 
al. in their 2005 study (Stanford et al., 2009).  
 Using the linkage of one of the regions found in the Xu et al. (2005) study, Zheng 
et al. (2005) conducted a fine mapping linkage analysis and evaluation of candidate gene 
NKX3.1 located at 8p21.  This gene was selected because of its known function and 
location within a chromosomal region where evidence for PrCa linkage and somatic loss 
of heterozygosity is found.  NKX3.1 is a homeodomain-containing transcription factor 
that is expressed in a largely prostate-specific and androgen-regulated manner (Zheng et 
al., 2005).  The protein producing NKX3.1 gene exerts a growth-suppressive and 
differentiating effect on prostate epithelial cells (Bowen, et al., 2000).  To examine this 
gene, the researchers re-sequenced the gene from159 probands with a diagnosis of cancer 
who provided a hereditary PrCa family history, each family with at least three first-
degree relatives affected with PrCa.  This study was the first report in which germ-line 
variants of the NKX3.1 gene, a gene largely prostate-specific and commonly deleted in 
prostate tumors, were systematically evaluated in a large number of hereditary PrCa 
families.  Both common and rare germ-line variants in the NKX3.1 gene were identified 
and were linked to PrCa risk in 188 hereditary PrCa families (Zheng et al, 2005).   
 Researchers using a recent case-control study conducted an analysis of 13 PrCa 
susceptibility chromosomal loci to study the genetic associations with family history and 
clinical features.  It was found that 11 single nucleotide polymorphisms (SNPs) were 
significantly associated with PrCa risk in their EuAm population.  The strongest 
association was found with 10q11 and 17q12 (OR= 1.21; 95% CI 1.17-1.47; OR= 0.77; 
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95% CI 0.69-0.86 respectively), demonstrating that the PrCa cases were 1.21 times more 
likely to have the 10q11 polymorphism than the study controls.  Similarly PrCa cases 
were 0.77 times more likely to have the 17q12 polymorphism than the study controls.  
Like older studies that specifically examined aggregation of PrCa, this study found an OR 
of 2.19 (95% CI 1.77-2.74; p < 0.0001) in EuAm men with a first-degree family history 
of disease (Fitzgerald, 2009).   
Gene alterations on chromosomes 1, 17, and the X-chromosome have been 
extensively studied and are associated with a family history of PrCa.  The hereditary 
PrCa (HPC1) gene and the ‘predisposing for cancer of the prostate’ (PCAP) gene are on 
chromosome 1, while the ‘human PrCa gene’ is on the X chromosome.  In addition, much 
like percentages seen with the breast and ovarian cancer syndrome, genetic studies 
targeting PrCa suggest a strong familial predisposition may be responsible for as many as 
5-10% of PrCa cases (Ford et al., 1998; Gronberg et al., 2003; Theodorescu et al., 2009).   
The proposed patterns of inheritance for PrCa are autosomal dominant inheritance 
and X-linked recessive inheritance (Carter, Beaty, Steinberg, Childs, & Walsh, 1992; 
Monroe et al., 1995).  Inherited polymorphic variants of genes mediating androgen 
action, AR (CYP17, and SRD5A2) also influence the development and progression of 
PrCa (Nelson, De Marzo, & Isaacs 2003).  The list of genes and polymorphisms linked to 
PrCa continue to grow.   
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Acquired Genetic/Genomic Injuries 
 
Chronic Inflammation 
 
PrCa is a multifactorial disease with many epigenetic risk factors.  The following 
paragraphs summarize some hypothesis about the epigenetics of PrCa.  Inflammation 
caused by repeated or chronic infections or inflammatory processes may also contribute 
to PrCa (Vasto et al., 2008).  One theory is that inflammation may lead to cell DNA 
damage, which can initiate or contribute to the cancerous transformation of prostate cells.  
Two inherited prostate susceptibility genes, RNASEL and MSR1, may have roles in 
response to infections, raising the possibility that prostate infection or inflammation 
initiates carcinogenesis in the prostate (Beuten et al., 2010).  
Researchers have identified a prostate-cancer-precursor lesion referred to as 
proliferative inflammatory atrophy (PIA).  Researchers have hypothesized that cells in 
PIA give rise to carcinoma by the development of high-grade prostate intraepithelial 
neoplasia (HGPIN) (Wang, Bergh, & Damber, 2009).  This study found clusters of 
atypical epithelial cell hyperplasia (a cell change known to be a precursor to cancer) 
inside PIA lesions, particularly in areas of intense focal chronic inflammation.  Wang, 
Berg, & Damber (2009) concluded that the PIA lesions are the earliest precursor lesions 
of HGPIN and PrCa and arise as a consequence of focal chronic inflammation.  These 
atypical cells may be a consequence of regenerative, proliferation after the activation of 
“stem cells” or their progeny by chronic stress (Wang, Berg, & Damber, 2009). 
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Geographics 
 
The incidence of and mortality due to PrCa are high in the US and Western 
Europe with the highest rates among black men in the United States.  Lower rates are 
more characteristic of those found in Asia (American Cancer Society, 2010).  The risk of 
PrCa among Asians increases as they immigrate to North America, implicating 
environmental and lifestyle-related factors associated with PrCa in the US (ACS, 2010).  
The AfAm Hereditary PrCa study, looking at the linkage of hereditary PrCa to 
chromosome 1q24, found that country of origin and racial group affect the incidence and 
extent of linkage of PrCa to specific loci.  They found that AfAms families with 
hereditary PrCa had >50% linkage on HPC1 (1q24-25) whereas EuAm and French 
hereditary PrCa families had 34% and 16% respectively.  In the analysis of linkage on 
Xq27 loci there was 0% linkage among AfAm families and 15% linkage among EuAm 
families.  Percentage of linkage was not reported for the French families (Powell et al., 
2001).  These findings suggest that the genetic variant contributing to PrCa in EuAms 
may be different from the genetic variant causing PrCa in AfAm populations (Powell et 
al., 2001).  
 
Diet 
 
 One of the most commonly reported environmental factors related to the risk of 
PrCa is diet.  Cell culture studies have shown that omega-6 fatty acids, found in fat, are 
positive stimulants of PrCa growth, while omega-3 fatty acids, found in soy, have a 
negative effect (Theodorescu, Mellon & Krupski, 2009).  These fats may exert their 
effects by alterations of sex hormones, growth factors, or through effects on 5-alpha 
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reductase.  Steroid 5α-reductase type II (SRD5A2) gene encodes the enzyme responsible 
for the conversion of testosterone to the metabolically more active dihydrotestosterone 
(Theodorescu, 2009).  Soy seems to decrease the growth of PrCa cells in mouse models; 
however, apart from epidemiologic factors, no direct evidence supports a beneficial effect 
in humans.  Soy products have phyto-oestrogens, especially flavonoids, which have a 
prophylactic effect on PrCa.  A meta-analysis of studies on soy consumption and 
isoflavones in association with PrCa risk found that soy consumption is associated with a 
reduction in PrCa risk in men (Yan and Spitznagel, 2009). 
A diet high in animal fat may lead to increased risk of PrCa, while a diet rich in 
soy may be protective (Yan and Spitznagel, 2009).  One suggestion is cooking meat at 
high temperatures, as done with charcoal grilling or frying, results in formation of very 
potent carcinogens such as heterocyclic amines (Nelson, De Marzo & Isaccs, 2003).  
 A diet rich in fruits and vegetables may also protect against PrCa.  Fruits and 
vegetables high in the antioxidant carotenoid lycopene, especially tomatoes, have been 
associated with a reduced risk of PrCa.  Diets rich in vitamin E may have some protective 
effects against PrCa mainly due to the antioxidants found in vitamin E (Gronberg, 2003).  
The antioxidant properties of selenium have also been studied and seem to have a 
protective effect against PrCa (Crawford, 2003; Gronberg, 2003; Nelson, et al., 2003)  
 The development of PrCa may also be linked to increased levels of certain 
hormones.  High levels of androgens, such as testosterone, promote prostate cell growth, 
and may contribute to PrCa risk in some men.  Insulin-like growth factor (IGF-1) is 
another hormone that has been linked to PrCa.  Some researchers have noted that men 
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with high levels of IGF-1 are more likely to develop PrCa (Crawford, 2003).  Tate, Bibb, 
& Larcom (2011) examined the effect of estrogens in cow’s milk on PrCa cells and found 
that cow’s milk stimulated the growth of PrCa cells in each of 14 separate experiments, 
producing an average increase in growth rate of over 30%.  Tate, Bibb & Larcom (2011) 
concluded that PrCa patients should be educated about the effect of dairy products on 
PrCa. Another study found men with diets high in dietary calcium, from milk, cottage 
cheese or yogurt, are also at increased risk for PrCa (Gronberg, 2003). 
 
Prostate Cancer (PrCa) in AfAm Men 
 
Researchers from Europe and the US have been studying PrCa since the mid-
1950s.  The increased incidence of PrCa in AfAms has been reported for centuries but the 
reason for this ethnic difference is still unclear.  One hypothesis of particular interest is 
that admixture in AfAms (mainly between European and African) contributes to the 
increased incidence of PrCa, considering Africans do not seem to have an increased 
incidence of mortality from PrCa (Sekine et al., 2002).  A study by the NIH stated that 
because of the recent admixture of AfAms (within the last 20 generations), their genomes 
have not been shuffled much by recombination since population mixing began (Smith, 
2004).  Tishkoff et al. (2010) studied 121 African populations, 4 AfAm population and 
60 non-African populations for patterns of variation at 1327 nuclear satellite and 
insertion/deletion markers.  They found that the ancestry of African-Americans is 
predominantly form Niger-Kordofanian (~71%), European (~13%) and other African 
(~8%) populations (Tiskhoff et al., 2010). 
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Additional hypothesis notes AfAms consume a diet high in animal fat and 
genetics is not the source of increased incidence and mortality of PrCa among AfAm 
men.  Cunningham et al., (2003) used the evidence provided by standardized incidence 
ratios (SIRs) in a familial aggregation study to conclude the increased incidence of PrCa 
in AfAms when compared with EuAms is not due to racial differences in the prevalence 
of germline mutations or other familial factors.  The SIRs for PrCa in first-degree 
relatives of AfAm (1.58, 1.05-2.29) and non-AfAm (EuAm and Hispanic Americans) 
(1.65, 1.06-2.15) probands are both increased and relatively similar.  The researchers 
interpreted this to mean that increased incidence of PrCa in AfAms is not due to racial 
differences in the prevalence of germline mutations or other familial factors.  Kang, 
Maygarden, Mohler, & Pruthi (2004), using a retrospective review, compared the clinical 
and pathological features in AfAm and EuAm patients with localized PrCa.  Their results 
indicate that AfAm men do not present at an earlier age and their clinical and 
pathological presentation was no different from that of EuAms.  This study concluded 
that AfAm men do not present with more aggressive PrCa.  However, those AfAm men 
who carry the highest load of genetic factors are at the highest risk for early 
dissemination of disease (Kang et al., 2004).  
More recent studies have found evidence that increased incidence of PrCa in 
AfAm men is due to variations in polymorphic allelic frequencies, whereas older studies 
sought evidence of rare single gene, germline mutations.  Rennert, Zeigler-Johnson and 
Addya (2011) found an association of susceptibility alleles in the genes ELAC2/HPC2, 
RNASEL/HPC1, and MSRI with PrCa severity in EuAm and AfAm men.  They found that 
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Arg462Gln of the RNASEL/HPC1 gene showed a very strong association with a positive 
family history and high-grade prostate tumor.  Other studies have also found evidence of 
HPC1 as a strong candidate gene for PrCa in the AfAm population (Brown et al., 2004).  
RNASEL/HPC1 is thought to be a tumor suppressor gene with functions to regulate cell 
proliferation and apoptosis (OMIM).  Kittles et al. (2006) concluded that the K1019x 
mutation of the EphB2 gene differs in frequency between AfAms and EuAms and this 
mutation is associated with increased risk for PrCa in AfAm men with a positive family 
history.  In an earlier study, Kittles et al. (2001) found that a cytosine nucleotide of the 
CYP17 polymorphism was significantly associated with increased PrCa risk and 
clinically advanced disease in AfAms.  The presence of at least on copy of the C (A2) 
allele was significantly higher among AfAm PrCa cases (69%), than among controls 
(50%); p- 0.01.  Of particular interest, no association was observed with family history 
and age at diagnosis and the CYP17 polymorphism (Kittles et al., 2001). 
Another possible difference in AfAm men and EuAm men is in hormone levels.  
AfAm men have increased levels of testosterone and these higher levels of testosterone 
may be related to increased incidence of PrCa (Theodorescu, 2009).  Elevated levels of 
testosterone are linked with alterations of the AR gene (Hu et al., 2010; Ross et al., 1998).  
Elevated levels of testosterone have also been linked to the CYP3A4 gene (Paris et al., 
1999).  This study found a positive association between being homozygous for the 
CYP3A4 variant in AfAm PrCa patients.  The CYP3A4 genetic variant, a protein 
belonging to the cytochrome P450 family, a point mutation of an adenine (A) to guanine 
(G) occurs in the 5’ regulatory region of the gene.  The protein product of this gene 
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oxidizes testosterone, which might also deactivate the hormone, although this is yet to be 
proven.  As a result men carrying the CYP3A4 variant allele may have more testosterone 
available to be converted to dihydrotestosterone, which is the main male sex hormone 
that regulates prostate cell division (Paris, et al., 1999). 
 
Conclusion 
 
There are multiple clinical and public health implications of family history as a 
predictor of genetic predisposition to PrCa.  Firstly, the empiric risk for the first-degree 
relative of a man with PrCa is 2 to3-fold compared to the lifetime risk of patients with no 
family history of disease (Carter, et al, 1993).  Use of a family health history can target 
persons with a family history and elevated risk of developing PrCa, but the goal of such 
knowledge is to empower men, not cripple them with fear and anxiety.  Educating at-risk 
individuals about lifestyle changes can promote health and prevent disease, make at-risk 
men better consumers of healthcare, better promoters of their personal health and the 
health of their family.  The key to decreasing health disparity related to any disease is 
education.  Education empowers at-risk individuals with information needed to prevent 
disease and promote overall health. 
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CHAPTER V 
 
SUMMARY AND CONCLUSION 
 
 
Summary 
 
 The public health burden of Prostate Cancer (PrCa) for African-American 
(AfAm) men is substantial.  AfAm have the highest incidence rate for PrCa in the United 
States and are more than twice as likely as European-American (EuAm) men to die of the 
malignancy.  The incidence rate for AfAm men is 255.5 and the mortality rate is 62.3 
compared to EuAm men with an incidence rate of 161.4 and mortality rate of 25.6 (NCI, 
2008).  This dissertation reviews the literature, describes the use of the ACCE model to 
test clinical validity of a tool used to identify incidence of inherited PrCa in AfAm males 
and analyze a case report which focuses on a family with multiple members with a PrCa 
diagnoses. 
 The review of the literature concluded that the analytical validity of self-reported 
family history is strong.  Family history of PrCa is usually accurate and the effect of 
recall bias is minimal.  There is some question as to the accuracy of family history as 
reported by AfAm men.  The one study comprised of an AfAm sample, found that 48% 
of AfAm changed their family history when surveyed a year later (Weinrich, Faison-
Smith, Hudson-Priest, Royal & Powell, 2002).  The literature for clinical validity and 
clinical utility related to family history of hereditary prostate cancer is inconclusive, due 
to the lack of a genetic test to confirm that men with pedigrees that indicate hereditary 
PrCa, actually harbor the same causative genotype.  There were no empirical studies that 
examined the ethical, legal, and social implications of family history of hereditary PrCa.  
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The gray literature that was reviewed focused on general ethical, legal and social issues 
related to the family history of inherited disorders in general with the greatest implication 
being the risk for breach of confidentiality and discrimination.  
The clinical validity portion of the ACCE model guided the evaluation of the 
piloted family history tool and pedigree analysis method.  In the pilot study eleven 
participants reported a personal family history of cancer.  One hereditary PrCa family 
was identified in the sample (N=49) and age was the only statistically detectable predictor 
of a personal history of PrCa (Likelihood Ratio Chi Square (χ2) = 10.193, p = 0.001).  
Two other predictor variables, number of brothers with PrCa and having a brother with 
PrCa approached significance (Likelihood ratio = 2.892, p = 0.089 and 6.711, p = 0.082) 
respectively.  Seven of the eleven participants that reported a personal history provided 
authorization for release of health information for the South Carolina Cancer Registry 
(SCCCR).  Four of the seven (57%) personal histories were linked positively to the 
SCCCR database.   
The case report reveals the visual impact of the pedigree, developed form the 
family history data, facilitating the identification of possible Mendelian patterns of 
inheritance.  More importantly the pedigree facilitates the identification of the at risk 
individuals.  The at risk individuals that are the focus of targeted health promotion and 
early screening programs.  
 
Conclusion 
 
This pilot study is the foundation for future research of genetic and genomic 
influences of PrCa disparity in AfAm males.  The small sample size was a significant 
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limitation of the pilot study, but statistical evidence of age as a predictor of PrCa and the 
near significance of other known predictors support the analytical validity of the piloted 
family history tool and pedigree analysis method. According to the National Cancer 
Institute (2012) 5-10% of the total cases of PrCa in the general population are hereditary 
PrCa.  Therefore, it was expected that out of 11 cases of PrCa there would be one case of 
hereditary PrCa.  In this study sample of 11 cases, one participant met the criteria for 
hereditary PrCa.  In addition the nearly parallel alignment of the age related incidence 
potentially indicates that the selected rural southern population is affected with PrCa in a 
manner that closely mimics that of the state and nation.  The investigator anticipates that 
improved design and statistical analysis will help to determine if the peak of incidence 
between the ages of 45-65 years in the pilot sample is an indication of potential 
hereditary PrCa or just a chance finding due to small sample size.  Finally, the novice 
investigator is also interested in gaining more experience with implementation of the 
ACCE model, in anticipation of a genetic test for hereditary prostate cancer in the very 
near future. 
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Appendix A 
 
Common Genetic Terms Used Throughout Manuscript 
 
Term Definition 
Allele An alternative or variable form of a gene at a specific 
chromosome location 
African-American (AfAm) “The term AfAm refers to a person of African 
ancestral origins who self identifies or is identified by 
others as AfAm.  While the term AfAm has been used 
at least since the 1920s, it has been the preferred term 
in the USA since the 1970s.  As most AfAms in the 
USA originated from sub-Saharan Africa, the term is 
not applied to Africans from northern African 
countries such as Morocco.  Most AfAms are 
descendants of persons brought to the Americas as 
slaves between the 17
th
 and 19th century (distant 
ancestry).  Such people differ from others who came 
from Africa or the Caribbean in the 20
th
 and 21st 
centuries (recent ancestry) in terms of culture, 
language, migration history, and health.  These 
differences are often ignored” (Agyemang, Bhopal, 
and Bruijnzeels, 2005, p. 1016). 
European American (EuAm) “EuAms are the most populous single ethnic group in 
the US according to United State census categories.  
EuAms are usually treated as a single population and 
the use of labels such as “white” or ‘Caucasian’ can 
propagate the illusion of genetic homogeneity.  
However, EuAms in fact form a structured population, 
due to historical immigration from diverse source 
populations” (Price et al., 2008, p. e236). 
Genome wide linkage scan  
 Genome wide association 
studies 
A scan of the genomes of thousands of individuals 
from a particular population who have a particular 
phenotype for single nucleotide polymorphisms that 
they share, but are much rarer in people who do not 
have the trait. 
Mapping linkage analysis Uses family pedigrees to follow the inheritance of a 
disorder over a few generations by looking for 
consistent, repeated inheritance of a particular region 
of the genome in family members with the disorder. 
Loss of heterozygosity When an individual goes from having one mutated 
allele and one wild allele to having two mutated 
alleles. 
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Germline mutation  A mutation in the germ cells (sperm and ova) and can 
be passed on to one’s children at conception. 
Single nucleotide 
polymorphisms 
A type of point mutation inherited in a gene that alters 
gene activity in a certain percentage of the general 
population. 
Epigenetic Biochemical factors that alter gene expression but do 
not involve changes in the DNA sequence. 
Homeodomain containing 
transcription factor  
A cluster of genes that encode transcription factors 
containing DNA-binding domain of approximately 60 
amino acids. 
Proband An affected family member coming to medical 
attention independent of other family members. 
Consultand Individual(s) seeking genetic counseling/testing. 
Admixture A measure of the proportion of different ancestral 
genetic contribution found in an individual. 
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Family History Tool and Demographic Form 
 
 
  
99 
 
 
 
  
100 
 
 
 
  
101 
 
 
 
 
 
 
 
  
102 
 
 
 
 
 
103 
 
 
 
 
104 
 
Appendix C 
 
Dissertation Research/Recruitment Contact Log 
 
 
Date 
 
Purpose of Contact 
 
Agency/Institution 
7/25/11 Collaboration with 
UsToo 
UsToo-Greenville Chapter 
8/12/11 Collaboration Breast and Prostate Awareness Forum 
Greenville West End community 
8/18/11 Collaboration SCCA-Prostate Work Group 
9/13/11 Attempt to 
establish contact 
with churches 
Anderson Ministerial Organization 
Scheduled for 10/25/11 
9/15/11 Collaboration Prostate Screening Panel-Russell House USC-
Columbia 
9/22/11 Collaboration-
guidance in 
completing 
application 
SCCCR 
9/19/11 1st letter went out 
to churches 
NA 
10/3/11 No response from 
letters 
 
10/9 /11 Attempt to 
establish contact 
with churches 
Provided contact information for Tumbling Shoals 
Baptist Association (Guy Sullivan) 
10/10/11 Attempt to 
establish contact 
with churches 
Moderator of Tumbling Shoals Baptist Association 
10/12/11 Attempt to 
establish contact 
with churches 
Provided contact for Rocky River Baptist 
Association 
(Donald R. Owens) 
10/13/11 Attempt to 
establish contact 
with churches 
Unable to contact Mr. Owens 
10/13/11 Schedule 
Presentation 
Scheduled presentation at Popular Springs AME for 
Oct 26th at 7:00 pm (Laurens)  
10/13/11 Attempt to 
establish contact 
with churches 
Unit 1- Rocky River Baptist Association 
On agenda for 10/29/11 at King David Baptist 
Church 
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Date Purpose of Contact Agency/Institution 
10/24/12 Attempt to 
establish contact 
with churches 
Tumbling Shoals 
(5 attendees) 
7:00 pm 
10/25/11 Attempt to 
establish contact 
with churches 
Anderson Ministerial Alliance 
12:00 pm 
(4 attendees) 
10/26/11 Presentation Popular Springs AME 
Johnny Payne also presented with me 
12/22/11 Attempt to 
establish contact 
with churches 
Welfare Baptist Church 
1/3/12 Attempt to 
establish contact 
with churches 
Mt Herman Baptist Church 
Scheduled for 2/5/2012 
1/3/12 Attempt to 
establish contact 
with churches 
Rocky River Baptist Association 
Scheduled time on agenda for 2/11/12 
2/5/12 Presentation Mt. Herman Baptist Church 
20 attendees 
2/11/12 Attempt to 
establish contact 
with churches 
Rocky River Baptist Church Mid-Winter Session 
 
1/19/12-
1/24/12 
Presentation School of Methods 
3/18/12 Presentation New Holly Light (9:00 am) 
3/25/12 Presentation Mt Moriah Baptist Church (11:00 am) 
4/1/12 Presentation Mt. Zion Baptist Church (11:00 am) 
4/15/12 Presentation Mt. Pleasant Baptist Church (11:00 am) 
4/29/12 Presentation Generostee Baptist Church (10:45 am) 
106 
 
Appendix D 
 
IRB Approval Letter 
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Appendix E 
 
IRB Information Letter 
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Appendix F 
 
Authorization for Release of Protected Health Information 
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Appendix G 
 
South Carolina Central Cancer Registry Statistics Fee Waiver 
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Appendix H 
 
Discovering History Education Workshop Presentation Documents 
 
Discovering HIStory Abbreviated Presentation  
 
 
 
 
 
 
Discovering HIStory Full Presentation 
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Appendix I 
 
Clemson University Healthcare Genetics Toolkit 
 
117 
 
 
118 
 
 
119 
 
 
120 
 
 
121 
 
 
